4g5j › Citations

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker.

Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, Kraemer O, Himmelsbach F, Haaksma E, Adolf GR
J Pharmacol Exp Ther 343 342-50 (2012)
Cited: 458 times
EuropePMC logo PMID: 22888144

Abstract

Deregulation of the ErbB (proto-oncogene B of the avian erythroblastosis virus AEV-H strain) receptor network is well recognized as an oncogenic driver in epithelial cancers. Several targeted drugs have been developed, including antibodies and small-molecule kinase inhibitors, each of them characterized by distinct patterns of ErbB receptor interactions. Understanding the precise pharmacological properties of these compounds is important for optimal use in clinical practice. Afatinib [BIBW 2992; N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide] is an ATP-competitive anilinoquinazoline derivative harboring a reactive acrylamide group. It was designed to covalently bind and irreversibly block enzymatically active ErbB receptor family members. Here, we show by X-ray crystallography the covalent binding of afatinib to wild-type epidermal growth factor receptor (EGFR) and by mass spectrometry the covalent interaction with EGFR, EGFRL858R/T790M, human epidermal growth factor receptor 2 (HER2), and ErbB-4. Afatinib potently inhibits the enymatic activity of ErbB-4 (EC50=1 nM) and the proliferation of cancer cell lines driven by multiple ErbB receptor aberrations at concentrations below 100 nM. N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butanamide (BI 37781), a close analog of afatinib lacking the acrylamide group and thus incapable of covalent bond formation, had similar potency on cells driven by EGFR or EGFRL858R, but less or no detectable activity on cells expressing EGFRL858R/T790M HER2 or ErbB-4. These results stress the importance of the acrylamide group and show that afatinib differs from approved ErbB targeting agents by irreversibly inhibiting the kinase activity of all ErbB family members. They provide a mechanistic rationale for the distinct pharmacological features of this compound and explain the clinical activity seen in some patients who are resistant to antibody or kinase inhibitor therapy because of secondary mutations or ErbB receptor "reprogramming."

Reviews - 4g5j mentioned but not cited (12)

  1. Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Gonzalez de Castro D, Clarke PA, Al-Lazikani B, Workman P. Clin. Pharmacol. Ther. 93 252-259 (2013)
  2. Kinase drug discovery 20 years after imatinib: progress and future directions. Cohen P, Cross D, Jänne PA. Nat Rev Drug Discov 20 551-569 (2021)
  3. Ten things you should know about protein kinases: IUPHAR Review 14. Fabbro D, Cowan-Jacob SW, Moebitz H. Br. J. Pharmacol. 172 2675-2700 (2015)
  4. A structural perspective on targeting the RTK/Ras/MAP kinase pathway in cancer. Heppner DE, Eck MJ. Protein Sci 30 1535-1553 (2021)
  5. Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism. Abourehab MAS, Alqahtani AM, Youssif BGM, Gouda AM. Molecules 26 6677 (2021)
  6. Impact of the Protein Data Bank on antineoplastic approvals. Westbrook JD, Soskind R, Hudson BP, Burley SK. Drug Discov Today 25 837-850 (2020)
  7. An overview of kinase downregulators and recent advances in discovery approaches. Wang B, Wu H, Hu C, Wang H, Liu J, Wang W, Liu Q. Signal Transduct Target Ther 6 423 (2021)
  8. Exploring the chemotherapeutic potential of currently used kinase inhibitors: An update. Naik RR, Shakya AK. Front Pharmacol 13 1064472 (2022)
  9. Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors. Amelia T, Kartasasmita RE, Ohwada T, Tjahjono DH. Molecules 27 819 (2022)
  10. Structure-Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017-Present). Șandor A, Ionuț I, Marc G, Oniga I, Eniu D, Oniga O. Pharmaceuticals (Basel) 16 534 (2023)
  11. Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma. Musumeci F, Cianciusi A, D'Agostino I, Grossi G, Carbone A, Schenone S. Molecules 26 7069 (2021)
  12. Technologies for Direct Detection of Covalent Protein-Drug Adducts. Mons E, Kim RQ, Mulder MPC. Pharmaceuticals (Basel) 16 547 (2023)

Articles - 4g5j mentioned but not cited (36)

  1. Molecular Basis for Redox Activation of Epidermal Growth Factor Receptor Kinase. Truong TH, Ung PM, Palde PB, Paulsen CE, Schlessinger A, Carroll KS. Cell Chem Biol 23 837-848 (2016)
  2. Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations. Suzawa K, Toyooka S, Sakaguchi M, Morita M, Yamamoto H, Tomida S, Ohtsuka T, Watanabe M, Hashida S, Maki Y, Soh J, Asano H, Tsukuda K, Miyoshi S. Cancer Sci. 107 45-52 (2016)
  3. Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor? Banno E, Togashi Y, Nakamura Y, Chiba M, Kobayashi Y, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K. Cancer Sci. 107 1134-1140 (2016)
  4. Delineation of Polypharmacology across the Human Structural Kinome Using a Functional Site Interaction Fingerprint Approach. Zhao Z, Xie L, Xie L, Bourne PE. J. Med. Chem. 59 4326-4341 (2016)
  5. Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer. Tsigelny IF, Wheler JJ, Greenberg JP, Kouznetsova VL, Stewart DJ, Bazhenova L, Kurzrock R. Oncotarget 6 6029-6039 (2015)
  6. Structural investigations of T854A mutation in EGFR and identification of novel inhibitors using structure activity relationships. Goyal S, Jamal S, Shanker A, Grover A. BMC Genomics 16 Suppl 5 S8 (2015)
  7. Complex Crystal Structures of EGFR with Third-Generation Kinase Inhibitors and Simultaneously Bound Allosteric Ligands. Niggenaber J, Heyden L, Grabe T, Müller MP, Lategahn J, Rauh D. ACS Med Chem Lett 11 2484-2490 (2020)
  8. EGFR: tale of the C-terminal tail. Gajiwala KS. Protein Sci. 22 995-999 (2013)
  9. Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity. Yoshizawa T, Uchibori K, Araki M, Matsumoto S, Ma B, Kanada R, Seto Y, Oh-Hara T, Koike S, Ariyasu R, Kitazono S, Ninomiya H, Takeuchi K, Yanagitani N, Takagi S, Kishi K, Fujita N, Okuno Y, Nishio M, Katayama R. NPJ Precis Oncol 5 32 (2021)
  10. Identifying three-dimensional structures of autophosphorylation complexes in crystals of protein kinases. Xu Q, Malecka KL, Fink L, Jordan EJ, Duffy E, Kolander S, Peterson JR, Dunbrack RL. Sci Signal 8 rs13 (2015)
  11. Landscape of drug-resistance mutations in kinase regulatory hotspots. Kim P, Li H, Wang J, Zhao Z. Brief Bioinform 22 bbaa108 (2021)
  12. Using machine learning to improve ensemble docking for drug discovery. Chandak T, Mayginnes JP, Mayes H, Wong CF. Proteins 88 1263-1270 (2020)
  13. A novel interaction fingerprint derived from per atom score contributions: exhaustive evaluation of interaction fingerprint performance in docking based virtual screening. Jasper JB, Humbeck L, Brinkjost T, Koch O. J Cheminform 10 15 (2018)
  14. Covalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 (TRIB2) pseudokinase in cancer cells. Foulkes DM, Byrne DP, Yeung W, Shrestha S, Bailey FP, Ferries S, Eyers CE, Keeshan K, Wells C, Drewry DH, Zuercher WJ, Kannan N, Eyers PA. Sci Signal 11 (2018)
  15. Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent. Liu W, Ning JF, Meng QW, Hu J, Zhao YB, Liu C, Cai L. Drug Des Devel Ther 9 3837-3851 (2015)
  16. An unbiased in vitro screen for activating epidermal growth factor receptor mutations. Chakroborty D, Kurppa KJ, Paatero I, Ojala VK, Koivu M, Tamirat MZ, Koivunen JP, Jänne PA, Johnson MS, Elo LL, Elenius K. J. Biol. Chem. 294 9377-9389 (2019)
  17. EDock-ML: A web server for using ensemble docking with machine learning to aid drug discovery. Chandak T, Wong CF. Protein Sci 30 1087-1097 (2021)
  18. Identification of afzelin potential targets in inhibiting triple-negative breast cancer cell migration using reverse docking. Rachmi E, Purnomo BB, Endharti AT, Fitri LE. Porto Biomed J 5 e095 (2020)
  19. Introduction to the BioChemical Library (BCL): An Application-Based Open-Source Toolkit for Integrated Cheminformatics and Machine Learning in Computer-Aided Drug Discovery. Brown BP, Vu O, Geanes AR, Kothiwale S, Butkiewicz M, Lowe EW, Mueller R, Pape R, Mendenhall J, Meiler J. Front Pharmacol 13 833099 (2022)
  20. Quantitative Structure-Mutation-Activity Relationship Tests (QSMART) model for protein kinase inhibitor response prediction. Huang LC, Yeung W, Wang Y, Cheng H, Venkat A, Li S, Ma P, Rasheed K, Kannan N. BMC Bioinformatics 21 520 (2020)
  21. Study of Imidazolium Salt Derivatives as PIK3CA Inhibitors Using a Comprehensive in Silico Method. Wang MY, Liang JW, Li XY, Olounfeh KM, Li SL, Wang S, Wang L, Meng FH. Int J Mol Sci 19 E896 (2018)
  22. "From molecular to clinic": The pivotal role of CDC42 in pathophysiology of human papilloma virus related cancers and a correlated sensitivity of afatinib. Wei E, Li J, Anand P, French LE, Wattad A, Clanner-Engelshofen B, Reinholz M. Front Immunol 14 1118458 (2023)
  23. EGFR uncommon alterations in advanced non-small cell lung cancer and structural insights into sensitivity to diverse tyrosine kinase inhibitors. Xu H, Yang G, Liu R, Yang Y, Li W, Li J, Hao X, Xing P, Wang Y. Front Pharmacol 13 976731 (2022)
  24. A novel near-infrared EGFR targeting probe for metastatic lymph node imaging in preclinical mouse models. Xie D, Li Y, Shi J, Zhu YP, Wang Y, Butch CJ, Wang Z. J Nanobiotechnology 21 342 (2023)
  25. A novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivatives. do Amaral DN, Lategahn J, Fokoue HH, da Silva EMB, Sant'Anna CMR, Rauh D, Barreiro EJ, Laufer S, Lima LM. Sci Rep 9 14 (2019)
  26. Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor. Jang J, Son J, Park E, Kosaka T, Saxon JA, De Clercq DJH, Choi HG, Tanizaki J, Eck MJ, Jänne PA, Gray NS. Angew. Chem. Int. Ed. Engl. 57 11629-11633 (2018)
  27. Exploring kinase family inhibitors and their moiety preferences using deep SHapley additive exPlanations. Fan YW, Liu WH, Chen YT, Hsu YC, Pathak N, Huang YW, Yang JM. BMC Bioinformatics 23 242 (2022)
  28. Genomic Profiling of Driver Gene Mutations in Chinese Patients With Non-Small Cell Lung Cancer. Meng H, Guo X, Sun D, Liang Y, Lang J, Han Y, Lu Q, Zhang Y, An Y, Tian G, Yuan D, Xu S, Geng J. Front Genet 10 1008 (2019)
  29. Molecular Recognition of FDA-Approved Small Molecule Protein Kinase Drugs in Protein Kinases. Zhu Y, Hu X. Molecules 27 7124 (2022)
  30. Precision Targeting of Endogenous Epidermal Growth Factor Receptor (EGFR) by Structurally Aligned Dual-Modifier Labeling. de Jesus Salazar-Estrada I, Kamath KS, Liu F. ACS Pharmacol Transl Sci 5 859-871 (2022)
  31. Strategy toward Kinase-Selective Drug Discovery. Zhang M, Liu Y, Jang H, Nussinov R. J Chem Theory Comput 19 1615-1628 (2023)
  32. Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A. Horton JR, Woodcock CB, Chen Q, Liu X, Zhang X, Shanks J, Rai G, Mott BT, Jansen DJ, Kales SC, Henderson MJ, Cyr M, Pohida K, Hu X, Shah P, Xu X, Jadhav A, Maloney DJ, Hall MD, Simeonov A, Fu H, Vertino PM, Cheng X. J. Med. Chem. 61 10588-10601 (2018)
  33. Structure-Guided Design of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors. Hao Y, Lyu J, Qu R, Sun D, Zhao Z, Chen Z, Ding J, Xie H, Xu Y, Li H. Sci Rep 7 3830 (2017)
  34. Successful Treatment of Afatinib Reversing Epidermal Growth Factor Receptor Exon19Deletion/G724S Mutation Resistance Guided by Protein-Drug Docking. Yu N, Xu Y, Wang X, Sun C, Qiu S, Guo Y, Bai M, Huang Y, Ma K. Oncologist 26 e1903-e1908 (2021)
  35. Targeting Cytotoxic Agents through EGFR-Mediated Covalent Binding and Release. Morese PA, Anthony N, Bodnarchuk M, Jennings C, Martin MP, Noble RA, Phillips N, Thomas HD, Wang LZ, Lister A, Noble MEM, Ward RA, Wedge SR, Stewart HL, Waring MJ. J Med Chem 66 12324-12341 (2023)
  36. Virtual Screening of Different Subclasses of Lignans with Anticancer Potential and Based on Genetic Profile. Maia MDS, Mendonça-Junior FJB, Rodrigues GCS, Silva ASD, Oliveira NIP, Silva PRD, Felipe CFB, Gurgel APAD, Nayarisseri A, Scotti MT, Scotti L. Molecules 28 6011 (2023)


Reviews citing this publication (147)

  1. The ErbB/HER family of protein-tyrosine kinases and cancer. Roskoski R. Pharmacol. Res. 79 34-74 (2014)
  2. FDA-approved small-molecule kinase inhibitors. Wu P, Nielsen TE, Clausen MH. Trends Pharmacol. Sci. 36 422-439 (2015)
  3. Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies. Hojjat-Farsangi M. Int J Mol Sci 15 13768-13801 (2014)
  4. Targeting RTK Signaling Pathways in Cancer. Regad T. Cancers (Basel) 7 1758-1784 (2015)
  5. ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors. Roskoski R. Pharmacol. Res. 87 42-59 (2014)
  6. Afatinib: first global approval. Dungo RT, Keating GM. Drugs 73 1503-1515 (2013)
  7. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC). Cohen RB. Cancer Treat. Rev. 40 567-577 (2014)
  8. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients. Roengvoraphoj M, Tsongalis GJ, Dragnev KH, Rigas JR. Cancer Treat. Rev. 39 839-850 (2013)
  9. Diarrhea associated with afatinib: an oral ErbB family blocker. Yang JC, Reguart N, Barinoff J, Köhler J, Uttenreuther-Fischer M, Stammberger U, O'Brien D, Wolf J, Cohen EE. Expert Rev Anticancer Ther 13 729-736 (2013)
  10. Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. Lacouture ME, Schadendorf D, Chu CY, Uttenreuther-Fischer M, Stammberger U, O'Brien D, Hauschild A. Expert Rev Anticancer Ther 13 721-728 (2013)
  11. A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. Modjtahedi H, Cho BC, Michel MC, Solca F. Naunyn Schmiedebergs Arch. Pharmacol. 387 505-521 (2014)
  12. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Liao BC, Lin CC, Yang JC. Curr Opin Oncol 27 94-101 (2015)
  13. Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer. Keating GM. Drugs 74 207-221 (2014)
  14. HER3, serious partner in crime: therapeutic approaches and potential biomarkers for effect of HER3-targeting. Kol A, Terwisscha van Scheltinga AG, Timmer-Bosscha H, Lamberts LE, Bensch F, de Vries EG, Schröder CP. Pharmacol. Ther. 143 1-11 (2014)
  15. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. Rolfo C, Giovannetti E, Hong DS, Bivona T, Raez LE, Bronte G, Buffoni L, Reguart N, Santos ES, Germonpre P, Taron M, Passiglia F, Van Meerbeeck JP, Russo A, Peeters M, Gil-Bazo I, Pauwels P, Rosell R. Cancer Treat. Rev. 40 990-1004 (2014)
  16. Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab. Gradishar WJ. Ann. Oncol. 24 2492-2500 (2013)
  17. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors. Juchum M, Günther M, Laufer SA. Drug Resist. Updat. 20 12-28 (2015)
  18. Clinical perspective of afatinib in non-small cell lung cancer. Chen X, Zhu Q, Zhu L, Pei D, Liu Y, Yin Y, Schuler M, Shu Y. Lung Cancer 81 155-161 (2013)
  19. Profile of neratinib and its potential in the treatment of breast cancer. Feldinger K, Kong A. Breast Cancer (Dove Med Press) 7 147-162 (2015)
  20. The design of covalent allosteric drugs. Nussinov R, Tsai CJ. Annu. Rev. Pharmacol. Toxicol. 55 249-267 (2015)
  21. Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis. Popat S, Mok T, Yang JC, Wu YL, Lungershausen J, Stammberger U, Griebsch I, Fonseca T, Paz-Ares L. Lung Cancer 85 230-238 (2014)
  22. Role of epidermal growth factor receptor in lung cancer and targeted therapies. Liu TC, Jin X, Wang Y, Wang K. Am J Cancer Res 7 187-202 (2017)
  23. Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors. Reguart N, Remon J. Future Oncol 11 1245-1257 (2015)
  24. Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib. Hirsh V. BioDrugs 29 167-183 (2015)
  25. EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now? -Ke EE, Wu YL. Trends Pharmacol. Sci. 37 887-903 (2016)
  26. Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer. Yap TA, Popat S. Pharmgenomics Pers Med 7 285-295 (2014)
  27. Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations. Haspinger ER, Agustoni F, Torri V, Gelsomino F, Gelsomino F, Platania M, Zilembo N, Gallucci R, Garassino MC, Cinquini M. Crit. Rev. Oncol. Hematol. 94 213-227 (2015)
  28. Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer. Tian W, Cao C, Shu L, Wu F. Onco Targets Ther 13 12113-12129 (2020)
  29. The challenge of blocking a wider family members of EGFR against head and neck squamous cell carcinomas. Martinez-Useros J, Garcia-Foncillas J. Oral Oncol. 51 423-430 (2015)
  30. Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer. Lee CC, Shiao HY, Wang WC, Hsieh HP. Expert Opin Investig Drugs 23 1333-1348 (2014)
  31. ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors. Deng J, Shao J, Markowitz JS, An G. Pharm. Res. 31 2237-2255 (2014)
  32. The Emerging Therapeutic Potential of Nitro Fatty Acids and Other Michael Acceptor-Containing Drugs for the Treatment of Inflammation and Cancer. Piesche M, Roos J, Kühn B, Fettel J, Hellmuth N, Brat C, Maucher IV, Awad O, Matrone C, Comerma Steffensen SG, Manolikakes G, Heinicke U, Zacharowski KD, Steinhilber D, Maier TJ. Front Pharmacol 11 1297 (2020)
  33. Clinical Pharmacokinetics and Pharmacodynamics of Afatinib. Wind S, Schnell D, Ebner T, Freiwald M, Stopfer P. Clin Pharmacokinet 56 235-250 (2017)
  34. Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer. Eroglu Z, Tagawa T, Somlo G. Oncologist 19 135-150 (2014)
  35. Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors. Sacco AG, Worden FP. Onco Targets Ther 9 1927-1943 (2016)
  36. Afatinib for the treatment of advanced non-small-cell lung cancer. Genova C, Rijavec E, Barletta G, Burrafato G, Biello F, Dal Bello MG, Coco S, Truini A, Alama A, Boccardo F, Grossi F, Grossi F. Expert Opin Pharmacother 15 889-903 (2014)
  37. Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3. Gaborit N, Lindzen M, Yarden Y. Hum Vaccin Immunother 12 576-592 (2016)
  38. Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies. Moreira J, Tobias A, O'Brien MP, Agulnik M. Drugs 77 843-857 (2017)
  39. Beyond EGFR TKI in EGFR-mutant non-small cell lung cancer patients: main challenges still to be overcome. Remon J, Morán T, Reguart N, Majem M, Carcereny E, Lianes P. Cancer Treat. Rev. 40 723-729 (2014)
  40. Squamous non-small cell lung cancer as a distinct clinical entity. Oliver TG, Patel J, Akerley W. Am. J. Clin. Oncol. 38 220-226 (2015)
  41. Privileged Electrophile Sensors: A Resource for Covalent Drug Development. Long MJC, Aye Y. Cell Chem Biol 24 787-800 (2017)
  42. The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer. Diver EJ, Foster R, Rueda BR, Growdon WB. Oncologist 20 1058-1068 (2015)
  43. Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications. Juan O, Popat S. Ther Adv Med Oncol 9 201-216 (2017)
  44. New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib. Hirsh V. Onco Targets Ther 10 2513-2526 (2017)
  45. Overcoming radioresistance in head and neck squamous cell carcinoma. Yamamoto VN, Thylur DS, Bauschard M, Schmale I, Sinha UK. Oral Oncol. 63 44-51 (2016)
  46. Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib. Santos ES, Hart L. Onco Targets Ther 13 9305-9321 (2020)
  47. Afatinib for the treatment of metastatic non-small cell lung cancer. Joshi M, Rizvi SM, Belani CP. Cancer Manag Res 7 75-82 (2015)
  48. Afatinib in the treatment of breast cancer. Hurvitz SA, Shatsky R, Harbeck N. Expert Opin Investig Drugs 23 1039-1047 (2014)
  49. Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer. Engle JA, Kolesar JM. Am J Health Syst Pharm 71 1933-1938 (2014)
  50. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer. Marquez-Medina D, Popat S. Future Oncol 11 2525-2540 (2015)
  51. Clinical and comparative utility of afatinib in non-small cell lung cancer. D'Arcangelo M, Hirsch FR. Biologics 8 183-192 (2014)
  52. New drug design with covalent modifiers. Adeniyi AA, Muthusamy R, Soliman ME. Expert Opin Drug Discov 11 79-90 (2016)
  53. The Exploration of Chirality for Improved Druggability within the Human Kinome. Saha D, Kharbanda A, Yan W, Lakkaniga NR, Frett B, Li HY. J Med Chem 63 441-469 (2020)
  54. The Potential of panHER Inhibition in Cancer. Wang X, Batty KM, Crowe PJ, Goldstein D, Yang JL. Front Oncol 5 2 (2015)
  55. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics. Chung C. J Oncol Pharm Pract 22 461-476 (2016)
  56. Afatinib: A Review in Advanced Non-Small Cell Lung Cancer. Keating GM. Target Oncol 11 825-835 (2016)
  57. Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview. Fischer PM. Med Res Rev 37 314-367 (2017)
  58. Dual targeting of HER3 and EGFR in colorectal tumors might overcome anti-EGFR resistance. Temraz S, Mukherji D, Shamseddine A. Crit. Rev. Oncol. Hematol. 101 151-157 (2016)
  59. Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy. Fasano M, Della Corte CM, Viscardi G, Di Liello R, Paragliola F, Sparano F, Iacovino ML, Castrichino A, Doria F, Sica A, Morgillo F, Colella G, Tartaro G, Cappabianca S, Testa D, Motta G, Ciardiello F. Ther Adv Med Oncol 13 1758835920949418 (2021)
  60. Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when? Girard N. Future Oncol 14 1117-1132 (2018)
  61. Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond. Delaney C, Frank S, Huang RS. Chin J Cancer 34 149-160 (2015)
  62. Targeting protein kinases with selective and semipromiscuous covalent inhibitors. Miller RM, Taunton J. Meth. Enzymol. 548 93-116 (2014)
  63. The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer. Stinchcombe TE. Curr Treat Options Oncol 17 18 (2016)
  64. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance. Jotte RM, Spigel DR. Cancer Med 4 1621-1632 (2015)
  65. Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence. Togashi Y, Hayashi H, Nakagawa K, Nishio K. Drug Des Devel Ther 8 1037-1046 (2014)
  66. Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance. Schrank Z, Chhabra G, Lin L, Iderzorig T, Osude C, Khan N, Kuckovic A, Singh S, Miller RJ, Puri N. Cancers (Basel) 10 (2018)
  67. Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future. Proto C, Imbimbo M, Gallucci R, Brissa A, Signorelli D, Vitali M, Macerelli M, Corrao G, Ganzinelli M, Greco FG, Garassino MC, Lo Russo G. Transl Lung Cancer Res 5 563-578 (2016)
  68. Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence. Wang X, Goldstein D, Crowe PJ, Yang JL. Onco Targets Ther 9 5461-5473 (2016)
  69. Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions. Recondo G, Dìaz Canton E, de la Vega M, Greco M, Recondo G, Valsecchi ME. World J Clin Oncol 5 440-454 (2014)
  70. Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs. Brückl W, Tufman A, Huber RM. Expert Rev Anticancer Ther 17 143-155 (2017)
  71. Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC). O'Leary C, Gasper H, Sahin KB, Tang M, Tang M, Kulasinghe A, Adams MN, Richard DJ, O'Byrne KJ. Pharmaceuticals (Basel) 13 E273 (2020)
  72. Head and neck cancer prevention: from primary prevention to impact of clinicians on reducing burden. Hashim D, Genden E, Posner M, Hashibe M, Boffetta P. Ann Oncol 30 744-756 (2019)
  73. Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer. You KS, Yi YW, Cho J, Park JS, Seong YS. Pharmaceuticals (Basel) 14 589 (2021)
  74. The importance of molecular profiling in predicting response to epidermal growth factor receptor family inhibitors in non-small-cell lung cancer: focus on clinical trial results. Tsao AS, Papadimitrakopoulou V. Clin Lung Cancer 14 311-321 (2013)
  75. A Structural View on Medicinal Chemistry Strategies against Drug Resistance. Agnello S, Brand M, Chellat MF, Gazzola S, Riedl R. Angew Chem Int Ed Engl 58 3300-3345 (2019)
  76. Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence. Ke EE, Wu YL. Ther Adv Respir Dis 10 256-264 (2016)
  77. New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong? Van Der Steen N, Caparello C, Rolfo C, Pauwels P, Peters GJ, Giovannetti E. Onco Targets Ther 9 6065-6074 (2016)
  78. Recent developments with rhodanine as a scaffold for drug discovery. Kaminskyy D, Kryshchyshyn A, Lesyk R. Expert Opin Drug Discov 12 1233-1252 (2017)
  79. Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far. Xu Y, Ding VW, Zhang H, Zhang X, Jablons D, He B. Ther Clin Risk Manag 12 807-816 (2016)
  80. Targeted Therapies for the Treatment of Brain Metastases in Solid Tumors. Bohn JP, Pall G, Stockhammer G, Steurer M. Target Oncol 11 263-275 (2016)
  81. Targeting EGFR Exon 20 Insertions in Non-Small Cell Lung Cancer: Recent Advances and Clinical Updates. Meador CB, Sequist LV, Piotrowska Z. Cancer Discov 11 2145-2157 (2021)
  82. Activating HER2 mutations as emerging targets in multiple solid cancers. Connell CM, Doherty GJ. ESMO Open 2 e000279 (2017)
  83. Afatinib and lung cancer. Jain P, Khanal R, Sharma A, Yan F, Sharma N. Expert Rev Anticancer Ther 14 1391-1406 (2014)
  84. Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress. Bennouna J, Moreno Vera SR. Future Oncol 12 355-372 (2016)
  85. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib. Morin-Ben Abdallah S, Hirsh V. Front Oncol 7 97 (2017)
  86. Mechanisms of EGFR Resistance in Glioblastoma. Pan PC, Magge RS. Int J Mol Sci 21 E8471 (2020)
  87. Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation. Bowles DW, McDermott JD, Jimeno A. Future Oncol 10 1065-1080 (2014)
  88. Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung. Hall PE, Spicer J, Popat S. Future Oncol 11 2175-2191 (2015)
  89. The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. Yuan J, Dong X, Yap J, Hu J. J Hematol Oncol 13 113 (2020)
  90. Treatment of head and neck cancer in the elderly. Hartmann S, Grandis JR. Expert Opin Pharmacother 17 1903-1921 (2016)
  91. Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. Angelbello AJ, Chen JL, Childs-Disney JL, Zhang P, Wang ZF, Disney MD. Chem. Rev. 118 1599-1663 (2018)
  92. Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer. Noda S, Kanda S. Expert Rev Respir Med 10 547-556 (2016)
  93. Afatinib in squamous cell carcinoma of the head and neck. Specenier P, Vermorken J. Expert Opin Pharmacother 17 1295-1301 (2016)
  94. Afatinib in the treatment of head and neck squamous cell carcinoma. Ferrarotto R, Gold KA. Expert Opin Investig Drugs 23 135-143 (2014)
  95. Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients. Wang LY, Cui JJ, Guo AX, Yin JY. Onco Targets Ther 11 529-538 (2018)
  96. Recent advances in targeted advanced lung cancer therapy in the elderly. Losanno T, Gridelli C. Expert Rev Anticancer Ther 17 787-797 (2017)
  97. Safety profiles of first-line therapies for metastatic non-squamous non-small-cell lung cancer. Losanno T, Gridelli C. Expert Opin Drug Saf 15 837-851 (2016)
  98. An overview of resistance to chemotherapy in osteosarcoma and future perspectives. Garcia-Ortega DY, Cabrera-Nieto SA, Caro-Sánchez HS, Cruz-Ramos M. Cancer Drug Resist 5 762-793 (2022)
  99. Banxia Xiexin Decoction () Combined with Afatinib in Treatment of Advanced Gallbladder Cancer: Case Report and Literature Review. Su L, Wang MM, Xu MR, Wang X, Xia HZ, Zhang M, Zheng L, Zhu YD, Wang MQ, Li P. Chin J Integr Med 25 303-306 (2019)
  100. Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine. Kim M, Kizilbash SH, Laramy JK, Gampa G, Parrish KE, Sarkaria JN, Elmquist WF. Pharm. Res. 35 177 (2018)
  101. Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles. Hossam M, Lasheen DS, Abouzid KA. Arch. Pharm. (Weinheim) 349 573-593 (2016)
  102. Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma. Wang Y, Guo Z, Li Y, Zhou Q. Open Med (Wars) 11 68-77 (2016)
  103. EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance. Fogli S, Polini B, Del Re M, Petrini I, Passaro A, Crucitta S, Rofi E, Danesi R. Pharmacogenomics 19 727-740 (2018)
  104. Early investigational drugs that target epidermal growth factor receptors for the treatment of head and neck cancer. Ugurluer G, Ozsahin M. Expert Opin Investig Drugs 23 1637-1654 (2014)
  105. First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option? Bulbul A, Husain H. Front Oncol 8 94 (2018)
  106. How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors. Milik SN, Lasheen DS, Serya RAT, Abouzid KAM. Eur J Med Chem 142 131-151 (2017)
  107. Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer. Kelly WJ, Shah NJ, Subramaniam DS. Front Oncol 8 208 (2018)
  108. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck. Campbell NP, Hensing TA, Bhayani MK, Shaikh AY, Brockstein BE. Expert Rev Anticancer Ther 16 847-858 (2016)
  109. The Taxonomy of Covalent Inhibitors. Tuley A, Fast W. Biochemistry 57 3326-3337 (2018)
  110. The role of afatinib in the management of non-small cell lung carcinoma. Yap TA, Popat S. Expert Opin Drug Metab Toxicol 9 1529-1539 (2013)
  111. Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design. Aggarwal C, Borghaei H. Oncologist 22 700-708 (2017)
  112. Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Mutation: First Line Treatment and Beyond. Rocco D, Battiloro C, Gravara LD, Gridelli C. Rev Recent Clin Trials 14 120-128 (2019)
  113. Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings. Harvey RD, Adams VR, Beardslee T, Medina P. J Oncol Pharm Pract 26 1461-1474 (2020)
  114. Atropisomerism in medicinal chemistry: challenges and opportunities. Toenjes ST, Gustafson JL. Future Med Chem 10 409-422 (2018)
  115. Biomarkers/Molecular Targets, Immunotherapy, and Treatments for Non-Small Cell Lung Cancer. Waxman ES, Fossella FV. J Adv Pract Oncol 7 514-524 (2016)
  116. Clinical development of targeted and immune based anti-cancer therapies. Seebacher NA, Stacy AE, Porter GM, Merlot AM. J. Exp. Clin. Cancer Res. 38 156 (2019)
  117. Drug-Drug Interactions, Safety, and Pharmacokinetics of EGFR Tyrosine Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer. Kucharczuk CR, Ganetsky A, Vozniak JM. J Adv Pract Oncol 9 189-200 (2018)
  118. Glioblastoma pharmacotherapy: A multifaceted perspective of conventional and emerging treatments (Review). Sevastre AS, Costachi A, Tataranu LG, Brandusa C, Artene SA, Stovicek O, Alexandru O, Danoiu S, Sfredel V, Dricu A. Exp Ther Med 22 1408 (2021)
  119. Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in EGFR activating mutation-positive advanced non-small-cell lung cancer. Abdallah SM, Hirsh V. Curr Oncol 25 S9-S17 (2018)
  120. Novel biomolecules in targeted cancer therapy: a new approach towards precision medicine. Kannampuzha S, Murali R, Gopalakrishnan AV, Mukherjee AG, Wanjari UR, Namachivayam A, George A, Dey A, Vellingiri B. Med Oncol 40 323 (2023)
  121. Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials. O'Kane GM, Barnes TA, Leighl NB. Curr Oncol 25 S28-S37 (2018)
  122. Role of afatinib in the treatment of advanced lung squamous cell carcinoma. Vavalà T. Clin Pharmacol 9 147-157 (2017)
  123. Safety of gefitinib in non-small cell lung cancer treatment. Hsiue EH, Lee JH, Lin CC, Yang JC. Expert Opin Drug Saf 15 993-1000 (2016)
  124. Targeted therapeutic options and future perspectives for HER2-positive breast cancer. Wang J, Xu B. Signal Transduct Target Ther 4 34 (2019)
  125. [TKI Resistance for T790M Mutation]. Wang H, Guo R, Zhang L. Zhongguo Fei Ai Za Zhi 18 245-250 (2015)
  126. Advanced diagnostic and therapeutic strategies in nanotechnology for lung cancer. Duan Y, Shen C, Zhang Y, Luo Y. Front Oncol 12 1031000 (2022)
  127. Afatinib as first-line treatment for advanced lung adenocarcinoma patients harboring HER2 mutation: A case report and review of the literature. Shi Y, Wang M. Thorac Cancer 9 1788-1794 (2018)
  128. Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature. Xu H, Liang Q, Xu X, Tan S, Wang S, Liu Y, Liu L. World J Surg Oncol 19 330 (2021)
  129. Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review. Jiang Y, Fang X, Xiang Y, Fang T, Liu J, Lu K. Curr Oncol 30 5337-5349 (2023)
  130. Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience. Ricciuti B, Baglivo S, De Giglio A, Chiari R. Ther Adv Respir Dis 12 1753466618808659 (2018)
  131. Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options? Abdallah SM, Wong A. Curr Oncol 25 S103-S114 (2018)
  132. Cardiac safety of afatinib: a review of data from clinical trials. Ewer MS, Patel K, O'Brien D, Lorence RM. Cardiooncology 1 3 (2015)
  133. Cardiovascular Complications Associated with Contemporary Lung Cancer Treatments. Sase K, Fujisaka Y, Shoji M, Mukai M. Curr Treat Options Oncol 22 71 (2021)
  134. Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer. Zaborowska-Szmit M, Krzakowski M, Kowalski DM, Szmit S. J Clin Med 9 (2020)
  135. Comparative review of drug-drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer. Xu ZY, Li JL. Onco Targets Ther 12 5467-5484 (2019)
  136. Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK Signaling. Raquel-Cunha A, Cardoso-Carneiro D, Reis RM, Martinho O. Cells 8 (2019)
  137. Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib. Lu S. Onco Targets Ther 12 1521-1538 (2019)
  138. EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients. Karachaliou N, Fernandez-Bruno M, Bracht JWP, Rosell R. Transl Cancer Res 8 S23-S47 (2019)
  139. Glioma-Targeted Therapeutics: Computer-Aided Drug Design Prospective. Poonan P, Agoni C, Ibrahim MAA, Soliman MES. Protein J 40 601-655 (2021)
  140. Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review. Pan L, Meng F, Wang W, Wang XH, Shen H, Bao P, Kang J, Kong D. Front Immunol 13 1072612 (2022)
  141. Radiolabeled EGFR TKI as predictive imaging biomarkers in NSCLC patients - an overview. Van De Stadt E, Yaqub M, Jahangir AA, Hendrikse H, Bahce I. Front Oncol 12 900450 (2022)
  142. Recent and current advances in PET/CT imaging in the field of predicting epidermal growth factor receptor mutations in non-small cell lung cancer. Hu N, Yan G, Wu Y, Wang L, Wang Y, Xiang Y, Lei P, Luo P. Front Oncol 12 879341 (2022)
  143. Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matter? Qin A, Musket A, Musich PR, Schweitzer JB, Xie Q. Neurooncol Adv 3 vdab133 (2021)
  144. Role of EGFR in the Nervous System. Romano R, Bucci C. Cells 9 (2020)
  145. Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer. Wang S, Li J. Onco Targets Ther 12 6535-6548 (2019)
  146. Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells. Hamid AB, Petreaca RC. Cancers (Basel) 12 (2020)
  147. The Development of Positron Emission Tomography Tracers for In Vivo Targeting the Kinase Domain of the Epidermal Growth Factor Receptor. Högnäsbacka A, Poot AJ, Vugts DJ, van Dongen GAMS, Windhorst AD. Pharmaceuticals (Basel) 15 450 (2022)

Articles citing this publication (263)

  1. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. J. Clin. Oncol. 31 3327-3334 (2013)
  2. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL. Lancet Oncol. 15 213-222 (2014)
  3. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Janjigian YY, Smit EF, Groen HJ, Horn L, Gettinger S, Camidge DR, Riely GJ, Wang B, Fu Y, Chand VK, Miller VA, Pao W. Cancer Discov 4 1036-1045 (2014)
  4. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. Katakami N, Atagi S, Goto K, Hida T, Horai T, Inoue A, Ichinose Y, Koboyashi K, Takeda K, Kiura K, Nishio K, Seki Y, Ebisawa R, Shahidi M, Yamamoto N. J. Clin. Oncol. 31 3335-3341 (2013)
  5. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TS, Zazulina V, Shahidi M, Lungershausen J, Massey D, Palmer M, Sequist LV. J. Clin. Oncol. 31 3342-3350 (2013)
  6. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies. Niederst MJ, Hu H, Mulvey HE, Lockerman EL, Garcia AR, Piotrowska Z, Sequist LV, Engelman JA. Clin. Cancer Res. 21 3924-3933 (2015)
  7. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, Clement PM, Gauler T, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G, de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Cohen EE, LUX-H&N 1 investigators. Lancet Oncol. 16 583-594 (2015)
  8. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. Hoffknecht P, Tufman A, Wehler T, Pelzer T, Wiewrodt R, Schütz M, Serke M, Stöhlmacher-Williams J, Märten A, Maria Huber R, Dickgreber NJ, Afatinib Compassionate Use Consortium (ACUC). J Thorac Oncol 10 156-163 (2015)
  9. HER2 aberrations in cancer: implications for therapy. Yan M, Parker BA, Schwab R, Kurzrock R. Cancer Treat. Rev. 40 770-780 (2014)
  10. A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors. Lanning BR, Whitby LR, Dix MM, Douhan J, Gilbert AM, Hett EC, Johnson TO, Joslyn C, Kath JC, Niessen S, Roberts LR, Schnute ME, Wang C, Hulce JJ, Wei B, Whiteley LO, Hayward MM, Cravatt BF. Nat. Chem. Biol. 10 760-767 (2014)
  11. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. Wu SG, Liu YN, Tsai MF, Chang YL, Yu CJ, Yang PC, Yang JC, Wen YF, Shih JY. Oncotarget 7 12404-12413 (2016)
  12. A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Seiwert TY, Fayette J, Cupissol D, Del Campo JM, Clement PM, Hitt R, Degardin M, Zhang W, Blackman A, Ehrnrooth E, Cohen EE. Ann. Oncol. 25 1813-1820 (2014)
  13. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Schuler M, Yang JC, Park K, Kim JH, Bennouna J, Chen YM, Chouaid C, De Marinis F, Feng JF, Grossi F, Kim DW, Liu X, Lu S, Strausz J, Vinnyk Y, Wiewrodt R, Zhou C, Wang B, Chand VK, Planchard D, LUX-Lung 5 Investigators. Ann. Oncol. 27 417-423 (2016)
  14. NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. Blakely CM, Pazarentzos E, Olivas V, Asthana S, Yan JJ, Tan I, Hrustanovic G, Chan E, Lin L, Neel DS, Newton W, Bobb KL, Fouts TR, Meshulam J, Gubens MA, Jablons DM, Johnson JR, Bandyopadhyay S, Krogan NJ, Bivona TG. Cell Rep 11 98-110 (2015)
  15. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. Tan L, Wang J, Tanizaki J, Huang Z, Aref AR, Rusan M, Zhu SJ, Zhang Y, Ercan D, Liao RG, Capelletti M, Zhou W, Hur W, Kim N, Sim T, Gaudet S, Barbie DA, Yeh JR, Yun CH, Hammerman PS, Mohammadi M, Jänne PA, Gray NS. Proc. Natl. Acad. Sci. U.S.A. 111 E4869-77 (2014)
  16. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions. Peters S, Zimmermann S, Adjei AA. Cancer Treat. Rev. 40 917-926 (2014)
  17. Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours. Wind S, Schmid M, Erhardt J, Goeldner RG, Stopfer P. Clin Pharmacokinet 52 1101-1109 (2013)
  18. Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. Yang JC, Sequist LV, Zhou C, Schuler M, Geater SL, Mok T, Hu CP, Yamamoto N, Feng J, O'Byrne K, Lu S, Hirsh V, Huang Y, Sebastian M, Okamoto I, Dickgreber N, Shah R, Märten A, Massey D, Wind S, Wu YL. Ann. Oncol. 27 2103-2110 (2016)
  19. Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Reardon DA, Nabors LB, Mason WP, Perry JR, Shapiro W, Kavan P, Mathieu D, Phuphanich S, Cseh A, Fu Y, Cong J, Wind S, Eisenstat DD, BI 1200 36 Trial Group and the Canadian Brain Tumour Consortium. Neuro-oncology 17 430-439 (2015)
  20. Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3. Kato T, Yoshioka H, Okamoto I, Yokoyama A, Hida T, Seto T, Kiura K, Massey D, Seki Y, Yamamoto N. Cancer Sci. 106 1202-1211 (2015)
  21. Comment Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer? Langer CJ. J. Clin. Oncol. 31 3303-3306 (2013)
  22. Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol. Goedken ER, Argiriadi MA, Banach DL, Fiamengo BA, Foley SE, Frank KE, George JS, Harris CM, Hobson AD, Ihle DC, Marcotte D, Merta PJ, Michalak ME, Murdock SE, Tomlinson MJ, Voss JW. J. Biol. Chem. 290 4573-4589 (2015)
  23. A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors. Marshall J, Hwang J, Eskens FA, Burger H, Malik S, Uttenreuther-Fischer M, Stopfer P, Ould-Kaci M, Cohen RB, Lewis NL. Invest New Drugs 31 399-408 (2013)
  24. Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir. Wind S, Giessmann T, Jungnik A, Brand T, Marzin K, Bertulis J, Hocke J, Gansser D, Stopfer P. Clin Drug Investig 34 173-182 (2014)
  25. Targeting EGF-receptor(s) - STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in human pancreatic cancer. Seshacharyulu P, Ponnusamy MP, Rachagani S, Lakshmanan I, Haridas D, Yan Y, Ganti AK, Batra SK. Oncotarget 6 5164-5181 (2015)
  26. Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions. Jackson PA, Widen JC, Harki DA, Brummond KM. J. Med. Chem. 60 839-885 (2017)
  27. Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. De Grève J, Moran T, Graas MP, Galdermans D, Vuylsteke P, Canon JL, Schallier D, Decoster L, Teugels E, Massey D, Chand VK, Vansteenkiste J. Lung Cancer 88 63-69 (2015)
  28. Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors. Freiwald M, Schmid U, Fleury A, Wind S, Stopfer P, Staab A. Cancer Chemother. Pharmacol. 73 759-770 (2014)
  29. Inhibition of β-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation. Togashi Y, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Tomida S, Nakagawa K, Nishio K. J Thorac Oncol 10 93-101 (2015)
  30. The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer. Lee TG, Jeong EH, Kim SY, Kim HR, Kim CH. Int. J. Cancer 136 2717-2729 (2015)
  31. A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors. Vermorken JB, Rottey S, Ehrnrooth E, Pelling K, Lahogue A, Wind S, Machiels JP. Ann. Oncol. 24 1392-1400 (2013)
  32. Afatinib down-regulates MCL-1 expression through the PERK-eIF2α-ATF4 axis and leads to apoptosis in head and neck squamous cell carcinoma. Liu X, Lv Z, Zou J, Liu X, Ma J, Wang J, Sa N, Jing P, Xu W. Am J Cancer Res 6 1708-1719 (2016)
  33. The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study. Burslem GM, Smith BE, Lai AC, Jaime-Figueroa S, McQuaid DC, Bondeson DP, Toure M, Dong H, Qian Y, Wang J, Crew AP, Hines J, Crews CM. Cell Chem Biol 25 67-77.e3 (2018)
  34. Selective Covalent Targeting of Anti-Apoptotic BFL-1 by Cysteine-Reactive Stapled Peptide Inhibitors. Huhn AJ, Guerra RM, Harvey EP, Bird GH, Walensky LD. Cell Chem Biol 23 1123-1134 (2016)
  35. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors. Heigener DF, Schumann C, Sebastian M, Sadjadian P, Stehle I, Märten A, Lüers A, Griesinger F, Scheffler M, Afatinib Compassionate Use Consortium (ACUC). Oncologist 20 1167-1174 (2015)
  36. Development of [18F]afatinib as new TKI-PET tracer for EGFR positive tumors. Slobbe P, Windhorst AD, Stigter-van Walsum M, Schuit RC, Smit EF, Niessen HG, Solca F, Stehle G, van Dongen GA, Poot AJ. Nucl. Med. Biol. 41 749-757 (2014)
  37. Pathway-Based Genomics Prediction using Generalized Elastic Net. Sokolov A, Carlin DE, Paull EO, Baertsch R, Stuart JM. PLoS Comput. Biol. 12 e1004790 (2016)
  38. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial. Burtness B, Bourhis JP, Vermorken JB, Harrington KJ, Cohen EE. Trials 15 469 (2014)
  39. A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing mice. Slobbe P, Windhorst AD, Stigter-van Walsum M, Smit EF, Niessen HG, Solca F, Stehle G, van Dongen GA, Poot AJ. EJNMMI Res 5 14 (2015)
  40. Drug resistance missense mutations in cancer are subject to evolutionary constraints. Friedman R. PLoS ONE 8 e82059 (2013)
  41. Effect of gefitinib plus Chinese herbal medicine (CHM) in patients with advanced non-small-cell lung cancer: a retrospective case-control study. Yang XB, Wu WY, Long SQ, Deng H, Pan ZQ. Complement Ther Med 22 1010-1018 (2014)
  42. Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer. Park H, Cho SY, Kim H, Na D, Han JY, Chae J, Park C, Park OK, Min S, Kang J, Choi B, Min J, Kwon JY, Suh YS, Kong SH, Lee HJ, Liu ET, Kim JI, Kim S, Yang HK, Lee C. Proc. Natl. Acad. Sci. U.S.A. 112 12492-12497 (2015)
  43. Inhibiting epidermal growth factor receptor at a distance. Sinclair JK, Denton EV, Schepartz A. J. Am. Chem. Soc. 136 11232-11235 (2014)
  44. Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment. Schnell D, Buschke S, Fuchs H, Gansser D, Goeldner RG, Uttenreuther-Fischer M, Stopfer P, Wind S, Petersen-Sylla M, Halabi A, Koenen R. Cancer Chemother. Pharmacol. 74 267-275 (2014)
  45. Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer. Marshall J, Shapiro GI, Uttenreuther-Fischer M, Ould-Kaci M, Stopfer P, Gordon MS. Future Oncol 9 271-281 (2013)
  46. Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial. Wu YL, Xu CR, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Märten A, Fan J, Peil B, Zhou C. Onco Targets Ther 11 8575-8587 (2018)
  47. Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. Molife LR, Omlin A, Jones RJ, Karavasilis V, Bloomfield D, Lumsden G, Fong PC, Olmos D, O'Sullivan JM, Pedley I, Hickish T, Jenkins P, Thompson E, Oommen N, Wheatley D, Heath C, Temple G, Pelling K, de Bono JS. Future Oncol 10 219-231 (2014)
  48. Evidence from mouse and man for a role of neuregulin 3 in nicotine dependence. Turner JR, Ray R, Lee B, Everett L, Xiang J, Jepson C, Kaestner KH, Lerman C, Blendy JA. Mol. Psychiatry 19 801-810 (2014)
  49. Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies. Pollock NI, Wang L, Wallweber G, Gooding WE, Huang W, Chenna A, Winslow J, Sen M, DeGrave KA, Li H, Zeng Y, Grandis JR. Clin. Cancer Res. 21 4597-4606 (2015)
  50. Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck. Harbeck N, Solca F, Gauler TC. Future Oncol 10 21-40 (2014)
  51. Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy. Machiels JP, Licitra LF, Haddad RI, Tahara M, Cohen EE. BMC Cancer 14 473 (2014)
  52. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer. Ding PN, Lord SJ, Gebski V, Links M, Bray V, Gralla RJ, Yang JC, Lee CK. J Thorac Oncol 12 633-643 (2017)
  53. Analysis of progression-free survival of first-line tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring leu858Arg or exon 19 deletions. Kuan FC, Li SH, Wang CL, Lin MH, Tsai YH, Yang CT. Oncotarget 8 1343-1353 (2017)
  54. HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Xu X, De Angelis C, Burke KA, Nardone A, Hu H, Qin L, Veeraraghavan J, Sethunath V, Heiser LM, Wang N, Ng CKY, Chen ES, Renwick A, Wang T, Nanda S, Shea M, Mitchell T, Rajendran M, Waters I, Zabransky DJ, Scott KL, Gutierrez C, Nagi C, Geyer FC, Chamness GC, Park BH, Shaw CA, Hilsenbeck SG, Rimawi MF, Gray JW, Weigelt B, Reis-Filho JS, Osborne CK, Schiff R. Clin. Cancer Res. 23 5123-5134 (2017)
  55. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer. Smith DL, Acquaviva J, Sequeira M, Jimenez JP, Zhang C, Sang J, Bates RC, Proia DA. Target Oncol 10 235-245 (2015)
  56. A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. Hickish T, Cassidy J, Propper D, Chau I, Falk S, Ford H, Iveson T, Braun M, Potter V, Macpherson IR, Finnigan H, Lee C, Jones H, Harrison M. Eur. J. Cancer 50 3136-3144 (2014)
  57. Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC). Codony-Servat C, Codony-Servat J, Karachaliou N, Molina MA, Chaib I, Ramirez JL, de Los Llanos Gil M, Solca F, Bivona TG, Rosell R. Oncotarget 8 47305-47316 (2017)
  58. Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells. Macha MA, Rachagani S, Qazi AK, Jahan R, Gupta S, Patel A, Seshacharyulu P, Lin C, Li S, Wang S, Verma V, Kishida S, Kishida M, Nakamura N, Kibe T, Lydiatt WM, Smith RB, Ganti AK, Jones DT, Batra SK, Jain M. Oncotarget 8 20961-20973 (2017)
  59. Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial. Clement PM, Gauler T, Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Cohen EE, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G, de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Vermorken JB, LUX-H&N 1 investigators. Ann. Oncol. 27 1585-1593 (2016)
  60. Design, synthesis and biological evaluation of novel 6-alkenylamides substituted of 4-anilinothieno[2,3-d]pyrimidines as irreversible epidermal growth factor receptor inhibitors. Ji X, Peng T, Zhang X, Li J, Yang W, Tong L, Qu R, Jiang H, Ding J, Xie H, Liu H. Bioorg. Med. Chem. 22 2366-2378 (2014)
  61. Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib. Schuler M, Fischer JR, Grohé C, Gütz S, Thomas M, Kimmich M, Schneider CP, Laack E, Märten A, Afatinib Compassionate Use Consortium. Oncologist 19 1100-1109 (2014)
  62. Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib. Kuo CS, Huang CH, Liu CY, Pavlidis S, Ko HW, Chung FT, Lin TY, Wang CL, Guo YK, Yang CT. Target Oncol 14 433-440 (2019)
  63. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours. Suder A, Ang JE, Kyle F, Harris D, Rudman S, Kristeleit R, Solca F, Uttenreuther-Fischer M, Pemberton K, Pelling K, Schnell D, de Bono J, Spicer J. Eur. J. Cancer 51 2275-2284 (2015)
  64. Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models. Ito K, Semba T, Uenaka T, Wakabayashi T, Asada M, Funahashi Y. Cancer Sci. 105 1023-1031 (2014)
  65. Mechanisms of and therapeutic approaches for overcoming resistance to epidermal growth factor receptor (EGFR)-targeted therapy in squamous cell carcinoma of the head and neck (SCCHN). Price KA, Cohen EE. Oral Oncol. 51 399-408 (2015)
  66. Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation. Kwak EL, Shapiro GI, Cohen SM, Becerra CR, Lenz HJ, Cheng WF, Su WC, Robohn M, Le Maulf F, Lobmeyer MT, Chand VK, Iafrate AJ. Cancer 119 3043-3051 (2013)
  67. Potential strategies for increasing drug-discovery productivity. Cumming JG, Finlay MR, Giordanetto F, Hemmerling M, Lister T, Sanganee H, Waring MJ. Future Med Chem 6 515-527 (2014)
  68. Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the epidermal growth factor receptor (EGFR) and c-Src: the concept of type III combi-targeting. Rao S, Larroque-Lombard AL, Peyrard L, Thauvin C, Rachid Z, Williams C, Jean-Claude BJ. PLoS ONE 10 e0117215 (2015)
  69. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. Lin YT, Chen JS, Liao WY, Ho CC, Hsu CL, Yang CY, Chen KY, Lee JH, Lin ZZ, Shih JY, Yang JC, Yu CJ. Int J Cancer 144 2887-2896 (2019)
  70. Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer. Umelo I, Noeparast A, Chen G, Renard M, Geers C, Vansteenkiste J, Giron P, De Wever O, Teugels E, De Grève J. Oncotarget 7 3068-3083 (2016)
  71. Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations. Jang J, To C, De Clercq DJH, Park E, Ponthier CM, Shin BH, Mushajiang M, Nowak RP, Fischer ES, Eck MJ, Jänne PA, Gray NS. Angew Chem Int Ed Engl 59 14481-14489 (2020)
  72. On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation. Brown BP, Zhang YK, Westover D, Yan Y, Qiao H, Huang V, Du Z, Smith JA, Ross JS, Miller VA, Ali S, Bazhenova L, Schrock AB, Meiler J, Lovly CM. Clin Cancer Res 25 3341-3351 (2019)
  73. Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors. Molife LR, Rudman SM, Alam S, Tan DS, Kristeleit H, Middleton G, Propper D, Bent L, Stopfer P, Uttenreuther-Fischer M, Wallenstein G, de Bono J, Spicer J. Cancer Chemother. Pharmacol. 72 1213-1222 (2013)
  74. Selective Inhibition of the Immunoproteasome by Structure-Based Targeting of a Non-catalytic Cysteine. Dubiella C, Baur R, Cui H, Huber EM, Groll M. Angew. Chem. Int. Ed. Engl. 54 15888-15891 (2015)
  75. Structural Differences between Wild-Type and Double Mutant EGFR Modulated by Third-Generation Kinase Inhibitors. Lowder MA, Doerner AE, Schepartz A. J. Am. Chem. Soc. 137 6456-6459 (2015)
  76. Therapeutic potential of an anti-HER2 single chain antibody-DM1 conjugates for the treatment of HER2-positive cancer. Zhang H, Wang Y, Wu Y, Jiang X, Tao Y, Yao Y, Peng Y, Chen X, Fu Y, Yu L, Wang R, Lai Q, Lai W, Li W, Kang Y, Yi S, Lu Y, Gou L, Wu M, Yang J. Signal Transduct Target Ther 2 17015 (2017)
  77. Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo. Young NR, Soneru C, Liu J, Grushko TA, Hardeman A, Olopade OI, Baum A, Solca F, Cohen EE. Target Oncol 10 501-508 (2015)
  78. Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status. Huguet F, Fernet M, Giocanti N, Favaudon V, Larsen AK. Target Oncol 11 371-381 (2016)
  79. Afatinib-loaded inhalable PLGA nanoparticles for localized therapy of non-small cell lung cancer (NSCLC)-development and in-vitro efficacy. Elbatanony RS, Parvathaneni V, Kulkarni NS, Shukla SK, Chauhan G, Kunda NK, Gupta V. Drug Deliv Transl Res 11 927-943 (2021)
  80. Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome. Rao S, Gurbani D, Du G, Everley RA, Browne CM, Chaikuad A, Tan L, Schröder M, Gondi S, Ficarro SB, Sim T, Kim ND, Berberich MJ, Knapp S, Marto JA, Westover KD, Sorger PK, Gray NS. Cell Chem Biol 26 818-829.e9 (2019)
  81. Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution. Jonsson VD, Blakely CM, Lin L, Asthana S, Matni N, Olivas V, Pazarentzos E, Gubens MA, Bastian BC, Taylor BS, Doyle JC, Bivona TG. Sci Rep 7 44206 (2017)
  82. Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer. Tanaka H, Taima K, Itoga M, Ishioka Y, Baba K, Shiratori T, Sakamoto H, Tsuchiya J, Nakagawa H, Hasegawa Y, Yasugahira H, Okudera K, Takanashi S, Tasaka S. Med Oncol 36 57 (2019)
  83. Symbiotic prodrugs (SymProDs) dual targeting of NFkappaB and CDK. Rana S, Kour S, Sonawane YA, Robb CM, Contreras JI, Kizhake S, Zahid M, Karpf AR, Natarajan A. Chem Biol Drug Des 96 773-784 (2020)
  84. A highly efficient and sensitive LC-MS/MS method for the determination of afatinib in human plasma: application to a metabolic stability study. Kadi AA, Abdelhameed AS, Darwish HW, Attwa MW, Al-Shakliah NS. Biomed. Chromatogr. 30 1248-1255 (2016)
  85. Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor. Zhang X, Peng T, Ji X, Li J, Tong L, Li Z, Yang W, Xu Y, Li M, Ding J, Jiang H, Xie H, Liu H. Bioorg. Med. Chem. 21 7988-7998 (2013)
  86. LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer. Köhler J, Schuler M. Future Oncol 10 533-540 (2014)
  87. The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations. Yang CJ, Tsai MJ, Hung JY, Lee MH, Tsai YM, Tsai YC, Hsu JF, Liu TC, Huang MS, Chong IW. BMC Pharmacol Toxicol 18 82 (2017)
  88. The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors. Hansen R, Peters U, Babbar A, Chen Y, Feng J, Janes MR, Li LS, Ren P, Liu Y, Zarrinkar PP. Nat. Struct. Mol. Biol. 25 454-462 (2018)
  89. Ultra High Performance Liquid Chromatography Method for the Determination of Two Recently FDA Approved TKIs in Human Plasma Using Diode Array Detection. Fouad M, Helvenstein M, Blankert B. J Anal Methods Chem 2015 215128 (2015)
  90. A phase I study of volasertib combined with afatinib, in advanced solid tumors. Machiels JP, Peeters M, Herremans C, Surmont V, Specenier P, De Smet M, Pilz K, Strelkowa N, Liu D, Rottey S. Cancer Chemother. Pharmacol. 76 843-851 (2015)
  91. A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027. Minegishi Y, Yamaguchi O, Sugawara S, Kuyama S, Watanabe S, Usui K, Mori M, Hataji O, Nukiwa T, Morita S, Kobayashi K, Gemma A. BMC Cancer 21 208 (2021)
  92. AZD8055 enhances in vivo efficacy of afatinib in chordomas. Zhao T, Siu IM, Williamson T, Zhang H, Ji C, Burger PC, Connis N, Ruzevick J, Xia M, Cottone L, Flanagan AM, Hann CL, Gallia GL. J Pathol 255 72-83 (2021)
  93. Afatinib ameliorates osteoclast differentiation and function through downregulation of RANK signaling pathways. Ihn HJ, Kim JA, Bae YC, Shin HI, Baek MC, Park EK. BMB Rep 50 150-155 (2017)
  94. Afatinib reverses ceritinib resistance (CR) in ALK/ROS1-positive non-small-cell lung cancer cell (NSCLC) via suppression of NRG1 pathway. Chen H, Zhang Q, Zhang Y, Jia B, Zhang B, Wang C. Onco Targets Ther 11 8201-8209 (2018)
  95. Blocking autophagy improves the anti-tumor activity of afatinib in lung adenocarcinoma with activating EGFR mutations in vitro and in vivo. Hu X, Shi S, Wang H, Yu X, Wang Q, Jiang S, Ju D, Ye L, Feng M. Sci Rep 7 4559 (2017)
  96. Brain Distribution of a Panel of Epidermal Growth Factor Receptor Inhibitors Using Cassette Dosing in Wild-Type and Abcb1/Abcg2-Deficient Mice. Kim M, Laramy JK, Mohammad AS, Talele S, Fisher J, Sarkaria JN, Elmquist WF. Drug Metab Dispos 47 393-404 (2019)
  97. Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance. Willemsen-Seegers N, Uitdehaag JCM, Prinsen MBW, de Vetter JRF, de Man J, Sawa M, Kawase Y, Buijsman RC, Zaman GJR. J. Mol. Biol. 429 574-586 (2017)
  98. Design, synthesis, and docking studies of afatinib analogs bearing cinnamamide moiety as potent EGFR inhibitors. Tu Y, OuYang Y, Xu S, Zhu Y, Li G, Sun C, Zheng P, Zhu W. Bioorg. Med. Chem. 24 1495-1503 (2016)
  99. Discovery of a potent dual ALK and EGFR T790M inhibitor. Jang J, Son JB, To C, Bahcall M, Kim SY, Kang SY, Mushajiang M, Lee Y, Jänne PA, Choi HG, Gray NS. Eur J Med Chem 136 497-510 (2017)
  100. Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study. Wiebe S, Schnell D, Külzer R, Gansser D, Weber A, Wallenstein G, Halabi A, Conrad A, Wind S. Eur J Drug Metab Pharmacokinet 42 461-469 (2017)
  101. Novel multi-targeted ErbB family inhibitor afatinib blocks EGF-induced signaling and induces apoptosis in neuroblastoma. Mao X, Chen Z, Zhao Y, Yu Y, Guan S, Woodfield SE, Vasudevan SA, Tao L, Pang JC, Lu J, Zhang H, Zhang F, Yang J. Oncotarget 8 1555-1568 (2017)
  102. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer. Mukai H, Masuda N, Ishiguro H, Mitsuma A, Shibata T, Yamamura J, Toi M, Watabe A, Sarashina A, Uttenreuther-Fischer M, Ando Y. Cancer Chemother. Pharmacol. 76 739-750 (2015)
  103. Pyrrocidine A, a metabolite of endophytic fungi, has a potent apoptosis-inducing activity against HL60 cells through caspase activation via the Michael addition. Uesugi S, Fujisawa N, Yoshida J, Watanabe M, Dan S, Yamori T, Shiono Y, Kimura K. J. Antibiot. 69 133-140 (2016)
  104. Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines. De Pauw I, Lardon F, Van den Bossche J, Baysal H, Fransen E, Deschoolmeester V, Pauwels P, Peeters M, Vermorken JB, Wouters A. Mol Oncol 12 830-854 (2018)
  105. Structural pharmacological studies on EGFR T790M/C797S. Kong LL, Ma R, Yao MY, Yan XE, Zhu SJ, Zhao P, Yun CH. Biochem. Biophys. Res. Commun. 488 266-272 (2017)
  106. A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors. Gordon MS, Springett GM, Su YB, Ould-Kaci M, Wind S, Zhao Y, LoRusso PM. Future Oncol 11 1479-1491 (2015)
  107. A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors. Chu QS, Sangha R, Hotte SJ, Sergenson G, Schnell D, Chand VK, Hirte HW. Invest New Drugs 32 1226-1235 (2014)
  108. Clinical analysis of patients treated with afatinib for advanced non-small cell lung cancer: A Nagano Lung Cancer Research Group observational study. Wada Y, Koyama S, Kuraishi H, Miyahara T, Yoshiike F, Agatsuma T, Yamamoto R, Ono Y, Suzuki T, Hachiya T, Gomi D, Tateishi K, Hanaoka M, Koizumi T. Respir Investig 54 462-467 (2016)
  109. Combined inhibition of rho-associated protein kinase and EGFR suppresses the invasive phenotype in EGFR-dependent lung cancer cells. Umelo IA, Wever OD, Kronenberger P, Noor A, Teugels E, Chen G, Bracke M, Grève JD. Lung Cancer 90 167-174 (2015)
  110. Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer. Canonici A, Browne AL, Ibrahim MFK, Fanning KP, Roche S, Conlon NT, O'Neill F, Meiller J, Cremona M, Morgan C, Hennessy BT, Eustace AJ, Solca F, O'Donovan N, Crown J. Ther Adv Med Oncol 12 1758835919897546 (2020)
  111. Comparing overall survival between first generation EGFR-TKIs and chemotherapy in lung cancer patients with Del19/L858R. Deng W, Lei Y, Liu S, Yang J, Tu H, Yan H, Wu Y. Chin. J. Cancer Res. 28 339-347 (2016)
  112. Design, synthesis, and docking studies of quinazoline analogues bearing aryl semicarbazone scaffolds as potent EGFR inhibitors. Tu Y, Wang C, Xu S, Lan Z, Li W, Han J, Zhou Y, Zheng P, Zhu W. Bioorg. Med. Chem. 25 3148-3157 (2017)
  113. EGFR blockade in GBM brain tumor stem cells synergizes with JAK2/STAT3 pathway inhibition to abrogate compensatory mechanisms in vitro and in vivo. Jensen KV, Hao X, Aman A, Luchman HA, Weiss S. Neurooncol Adv 2 vdaa020 (2020)
  114. EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models. Venugopalan A, Lee MJ, Niu G, Medina-Echeverz J, Tomita Y, Lizak MJ, Cultraro CM, Simpson RM, Chen X, Trepel JB, Guha U. Oncotarget 7 54137-54156 (2016)
  115. Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA. Otsubo K, Sakai K, Takeshita M, Harada D, Azuma K, Ota K, Akamatsu H, Goto K, Horiike A, Kurata T, Nakagaki N, Nosaki K, Iwama E, Nakanishi Y, Nishio K, Okamoto I. Oncologist 24 1022-1026 (2019)
  116. Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours. Bahleda R, Hollebecque A, Varga A, Gazzah A, Massard C, Deutsch E, Amellal N, Farace F, Ould-Kaci M, Roux F, Marzin K, Soria JC. Br. J. Cancer 113 1413-1420 (2015)
  117. Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy. Felip E, Hirsh V, Popat S, Cobo M, Fülöp A, Dayen C, Trigo JM, Gregg R, Waller CF, Soria JC, Goss GD, Gordon J, Wang B, Palmer M, Ehrnrooth E, Gadgeel SM. Clin Lung Cancer 19 74-83.e11 (2018)
  118. A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China. Tu HY, Feng J, Shi M, Zhao J, Wang Y, Chang J, Wang J, Cheng Y, Zhu J, Tan EH, Li K, Zhang Y, Lee V, Yang CT, Su WC, Lam DC, Srinivasa BJ, Rajappa S, Ho CL, Lam KC, Hu Y, Bondarde SA, Liu X, Tian Y, Xue Z, Cseh A, Huang DC, Zhou C, Wu YL. Target Oncol 17 1-13 (2022)
  119. A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors. Spicer J, Irshad S, Ang JE, Enting D, Kristeleit R, Uttenreuther-Fischer M, Pemberton K, Pelling K, Schnell D, de Bono J. Cancer Chemother. Pharmacol. 79 17-27 (2017)
  120. A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib. Moran T, Palmero R, Provencio M, Insa A, Majem M, Reguart N, Bosch-Barrera J, Isla D, Costa EC, Lee C, Puig M, Kraemer S, Schnell D, Rosell R. Lung Cancer 108 154-160 (2017)
  121. Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial. Saran F, Welsh L, James A, McBain C, Gattamaneni R, Jefferies S, Harris F, Pemberton K, Schaible J, Bender S, Cseh A, Brada M. J Neurooncol 155 307-317 (2021)
  122. Afatinib in advanced NSCLC: a profile of its use. Deeks ED, Keating GM. Drugs Ther Perspect 34 89-98 (2018)
  123. Afatinib induces pro-survival autophagy and increases sensitivity to apoptosis in stem-like HNSCC cells. Liu X, Suo H, Zhou S, Hou Z, Bu M, Liu X, Xu W. Cell Death Dis 12 728 (2021)
  124. Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study). Hata A, Katakami N, Kaji R, Yokoyama T, Kaneda T, Tamiya M, Inoue T, Kimura H, Yano Y, Tamura D, Morita S, Negoro S, The Hanshin Oncology Group F. Cancer 124 3830-3838 (2018)
  125. Conserved molecular mechanisms underlying the effects of small molecule xenobiotic chemotherapeutics on cells. Sarin H. Mol Clin Oncol 4 326-368 (2016)
  126. Covalent modifier-type aggregation inhibitor of amyloid-β based on a cyclo-KLVFF motif. Kino R, Araya T, Arai T, Sohma Y, Kanai M. Bioorg. Med. Chem. Lett. 25 2972-2975 (2015)
  127. Effect of combined irradiation and EGFR/Erb-B inhibition with BIBW 2992 on proliferation and tumour cure in cell lines and xenografts. Gurtner K, Ebert N, Pfitzmann D, Eicheler W, Zips D, Baumann M, Krause M. Radiat Oncol 9 261 (2014)
  128. Efficacy generated by afatinib in a lung adenocarcinoma patient harboring HER2 S310Y mutation. Wang J, Wen Y, Ding G, Ding P, Zhang L, Liu J, Zhang T, Yang L. Cancer Biol. Ther. 19 450-453 (2018)
  129. HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer. Canonici A, Ivers L, Conlon NT, Pedersen K, Gaynor N, Browne BC, O'Brien NA, Gullo G, Collins DM, O'Donovan N, Crown J. Invest New Drugs 37 441-451 (2019)
  130. Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia. Cheng W, Yuan Y, Qiu N, Peng P, Sheng R, Hu Y. Bioorg. Med. Chem. 22 6796-6805 (2014)
  131. Identifying EGFR mutation-induced drug resistance based on alpha shape model analysis of the dynamics. Ma L, Zou B, Yan H. Proteome Sci 14 12 (2016)
  132. Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations. Chen YC, Tsai MJ, Lee MH, Kuo CY, Shen MC, Tsai YM, Chen HC, Hung JY, Huang MS, Chong IW, Yang CJ. BMC Cancer 21 495 (2021)
  133. Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer. Tamura S, Wang Y, Veeneman B, Hovelson D, Bankhead A, Broses LJ, Lorenzatti Hiles G, Liebert M, Rubin JR, Day KC, Hussain M, Neamati N, Tomlins S, Palmbos PL, Grivas P, Day ML. Bladder Cancer 4 77-90 (2018)
  134. Prolonged survival with erlotinib followed by afatinib in a caucasian smoker with metastatic, poorly differentiated large cell carcinoma of the lung: a case report. Sala González MÁ. Cancer Biol. Ther. 16 1434-1437 (2015)
  135. Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer. Wang DD, Lee VH, Zhu G, Zou B, Ma L, Yan H. Mol Biosyst 12 1552-1563 (2016)
  136. Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity. Ueda H, Hayashi H, Kudo K, Takeda M, Nakagawa K. Invest New Drugs 34 797-799 (2016)
  137. Synergistic Growth Inhibition by Afatinib and Trametinib in Preclinical Oral Squamous Cell Carcinoma Models. Yee PS, Zainal NS, Gan CP, Lee BKB, Mun KS, Abraham MT, Ismail SM, Abdul Rahman ZA, Patel V, Cheong SC. Target Oncol 14 223-235 (2019)
  138. The myogenesis program drives clonal selection and drug resistance in rhabdomyosarcoma. Patel AG, Chen X, Huang X, Clay MR, Komorova N, Krasin MJ, Pappo A, Tillman H, Orr BA, McEvoy J, Gordon B, Blankenship K, Reilly C, Zhou X, Norrie JL, Karlstrom A, Yu J, Wodarz D, Stewart E, Dyer MA. Dev Cell 57 1226-1240.e8 (2022)
  139. Variations in EGFR ctDNA Correlates to the Clinical Efficacy of Afatinib in Non Small Cell Lung Cancer with Acquired Resistance. He J, Tan W, Tang X, Ma J. Pathol. Oncol. Res. 23 307-315 (2017)
  140. A High-Throughput Method for Measuring Drug Residence Time Using the Transcreener ADP Assay. Kumar M, Lowery RG. SLAS Discov 22 915-922 (2017)
  141. Research Support, Non-U.S. Gov't A case of multiple primary lung adenocarcinoma with a CD74-NRG1 fusion protein and HER2 mutation benefit from combined target therapy. Chen K, Li W, Xi X, Zhong J. Thorac Cancer 13 3063-3067 (2022)
  142. A chemoproteomic method for identifying cellular targets of covalent kinase inhibitors. Chen YC, Zhang C. Genes Cancer 7 148-153 (2016)
  143. Adipocyte-conditioned medium induces resistance of breast cancer cells to lapatinib. Geneste A, Duong MN, Molina L, Conilh L, Beaumel S, Cleret A, Chettab K, Lachat M, Jordheim LP, Matera EL, Dumontet C. BMC Pharmacol Toxicol 21 61 (2020)
  144. Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies. Passaro A, de Marinis F, Tu HY, Laktionov KK, Feng J, Poltoratskiy A, Zhao J, Tan EH, Gottfried M, Lee V, Kowalski D, Yang CT, Srinivasa BJ, Clementi L, Jalikop T, Huang DCL, Cseh A, Park K, Wu YL. Front Oncol 11 709877 (2021)
  145. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial. Goss GD, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Isla D, Morabito A, Min YJ, Ardizzoni A, Bender S, Cseh A, Felip E. EClinicalMedicine 37 100940 (2021)
  146. Comment Afatinib, a lung cancer inhibitor of ErbB family. de Antonellis P. Naunyn Schmiedebergs Arch. Pharmacol. 387 503-504 (2014)
  147. Bioequivalence study of dacomitinib and Vizimpro® in healthy Chinese volunteers under fasting and fed conditions: A randomized, open-label, single-dose, crossover trial. Yang X, Li J, Zhang T, Xia Q, Zhang W, Cui Y, He W. Clin Transl Sci 16 2591-2603 (2023)
  148. Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance. Zhang SR, Xu YS, Jin E, Zhu LC, Xia B, Chen XF, Li FZ, Ma SL. Acta Pharmacol. Sin. 38 100-109 (2017)
  149. Clinical analysis of EGFR-positive non-small cell lung cancer patients treated with first-line afatinib: A Nagano Lung Cancer Research Group. Sonehara K, Kobayashi T, Tateishi K, Morozumi N, Yoshiike F, Hachiya T, Ono Y, Takasuna K, Agatsuma T, Masubuchi T, Matsuo A, Tanaka H, Morikawa A, Hanaoka M, Koizumi T. Thorac Cancer 10 1078-1085 (2019)
  150. Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations. Tu CY, Chen CM, Liao WC, Wu BR, Chen CY, Chen WC, Hsia TC, Cheng WC, Chen CH. Oncotarget 9 24237-24247 (2018)
  151. Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR-T790M mutation in non-small cell lung cancer cells. Katayama Y, Yamada T, Tokuda S, Okura N, Nishioka N, Morimoto K, Tanimura K, Morimoto Y, Iwasaku M, Horinaka M, Sakai T, Kita K, Yano S, Takayama K. Cancer Med 11 944-955 (2022)
  152. Long progression-free survival with afatinib in a patient with EGFR-unknown lung adenocarcinoma after erlotinib failure: a case report. Vitale MG, Scagliarini S, Riccardi F, Barbato C, Otero M, Mocerino C, Ambrosio F, Cartenì G. Tumori 101 e64-6 (2015)
  153. Multi-center, randomized, double-blind, placebo-controlled, exploratory study to evaluate the efficacy and safety of HAD-B1 for dose-finding in EGFR positive and locally advanced or metastatic NSCLC subjects who need Afatinib therapy: Study protocol clinical trial (SPIRIT Compliant). Park SJ, Kang HJ, Jun HJ, Shin SH, Yoo HS. Medicine (Baltimore) 99 e18735 (2020)
  154. Comment Predictive biomarkers and EGFR inhibitors in squamous cell carcinoma of head and neck (SCCHN). Vigneswara V, Kong A. Ann. Oncol. 29 794-796 (2018)
  155. Synthesis and Anti-Tumor Activities of 4-Anilinoquinoline Derivatives. Liu D, Luan T, Kong J, Zhang Y, Wang HF. Molecules 21 E21 (2015)
  156. The Predictive Values of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon EGFR Mutations-The Mutation Patterns, Use of Different Generations of EGFR-TKIs, and Concurrent Genetic Alterations. Tan J, Hu C, Deng P, Wan R, Cao L, Li M, Yang H, Gu Q, An J, Jiang J. Front Oncol 11 646577 (2021)
  157. The guanine nucleotide exchange factor VAV3 participates in ERBB4-mediated cancer cell migration. Ojala VK, Knittle AM, Kirjalainen P, Merilahti JAM, Kortesoja M, Tvorogov D, Vaparanta K, Lin S, Kast J, Pulliainen AT, Kurppa KJ, Elenius K. J Biol Chem 295 11559-11571 (2020)
  158. The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M. Huang YH, Tseng JS, Hsu KH, Chen KC, Su KY, Yu SL, Chen JJW, Yang TY, Chang GC. Sci Rep 11 12084 (2021)
  159. Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series. Cadranel J, Liu SV, Duruisseaux M, Branden E, Goto Y, Weinberg BA, Heining C, Schlenk RF, Cheema P, Jones MR, Drilon A, Trombetta D, Muscarella LA, Tolba K, Gounant V, Cseh A, Solca F, Laskin JJ, Renouf DJ. Oncologist 26 7-16 (2021)
  160. Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts. Hu P, Han DX, Ruan RS, Zheng LM, Chou SH, Tzeng CM. Oncotarget 7 35741-35752 (2016)
  161. Treatment outcomes and safety of afatinib in advanced squamous cell lung cancer progressed after platinum-based doublet chemotherapy and immunotherapy (SPACE study). Lee SH, Park CK, Lee SY, Choi CM. Thorac Cancer 12 1264-1268 (2021)
  162. Unlocking the Mechanisms of Cutaneous Adverse Drug Reactions: Activation of the Phosphatidylinositol 3-Kinase/Protein Kinase B Pathway by EGFR Inhibitors Triggers Keratinocyte Differentiation and Polarization of Epidermal Immune Responses. Ondet T, Roux PF, Monshouwer M, Stamatas GN. JID Innov 1 100009 (2021)
  163. 5-Bromoindirubin 3'-(O-oxiran-2-ylmethyl)oxime: A long-acting anticancer agent and a suicide inhibitor for epoxide hydrolase. Ichimaru Y, Fujii T, Saito H, Sano M, Uchiyama T, Miyairi S. Bioorg. Med. Chem. 25 4665-4676 (2017)
  164. A Platform To Enhance Quantitative Single Molecule Localization Microscopy. Golfetto O, Wakefield DL, Cacao EE, Avery KN, Kenyon V, Jorand R, Tobin SJ, Biswas S, Gutierrez J, Clinton R, Ma Y, Horne DA, Williams JC, Jovanović-Talisman T. J. Am. Chem. Soc. 140 12785-12797 (2018)
  165. A novel EGFR exon 21 indel mutation in lung adenocarcinoma and response to dacomitinib: A case report. Zhou T, Xiong Q, Hong C, Wang Q, Wang W, Xu C, Cai J, Yangtze River Delta Lung Cancer Cooperation Group. Medicine (Baltimore) 101 e30269 (2022)
  166. A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors. O'Brien MER, Sarker D, Bhosle J, Thillai K, Yap TA, Uttenreuther-Fischer M, Pemberton K, Jin X, Wiebe S, de Bono J, Spicer J. Cancer Chemother. Pharmacol. 82 757-766 (2018)
  167. AZD4625 is a Potent and Selective Inhibitor of KRASG12C. Chakraborty A, Hanson L, Robinson D, Lewis H, Bickerton S, Davies M, Polanski R, Whiteley R, Koers A, Atkinson J, Baker T, Del Barco Barrantes I, Ciotta G, Kettle JG, Magiera L, Martins CP, Peter A, Wigmore E, Underwood Z, Cosulich S, Niedbala M, Ross S. Mol Cancer Ther 21 1535-1546 (2022)
  168. Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial. Hickish T, Mehta A, Liu MC, Huang CS, Arora RS, Chang YC, Yang Y, Vladimirov V, Jain M, Tsang J, Pemberton K, Sadrolhefazi B, Jin X, Tseng LM. Breast Cancer Res Treat 192 593-602 (2022)
  169. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. Vengoji R, Macha MA, Nimmakayala RK, Rachagani S, Siddiqui JA, Mallya K, Gorantla S, Jain M, Ponnusamy MP, Batra SK, Shonka N. J. Exp. Clin. Cancer Res. 38 266 (2019)
  170. Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study. Thongprasert S, Geater SL, Clement D, Abdelaziz A, Reyes-Igama J, Jovanovic D, Alexandru A, Schenker M, Sriuranpong V, Serwatowski P, Suresh S, Cseh A, Gaafar R. Lung Cancer Manag 8 LMT15 (2019)
  171. Afatinib, an EGFR inhibitor, decreases EMT and tumorigenesis of Huh‑7 cells by regulating the ERK‑VEGF/MMP9 signaling pathway. Chen Y, Chen X, Ding X, Wang Y. Mol Med Rep 20 3317-3325 (2019)
  172. An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations. Chakroborty D, Ojala VK, Knittle AM, Drexler J, Tamirat MZ, Ruzicka R, Bosch K, Woertl J, Schmittner S, Elo LL, Johnson MS, Kurppa KJ, Solca F, Elenius K. Cancer Res Commun 2 10-27 (2022)
  173. Case Reports Anterior Uveitis Caused by Ocular Side Effects of Afatinib: A Case Report. Todokoro D, Itakura H, Ibe T, Kishi S. Case Rep Ophthalmol 7 74-78 (2016)
  174. Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer. Harada Y, Sato A, Nakamura H, Kai K, Kitamura S, Nakamura T, Kurihara Y, Ikeda S, Sueoka E, Kimura S, Sueoka-Aragane N. BMC Cancer 23 77 (2023)
  175. Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation. Chen YJ, Hsu CC, Shiao YJ, Wang HT, Lo YL, Lin AMY. Sci Rep 9 2516 (2019)
  176. Anti-tumor activity of Shikonin against afatinib resistant non-small cell lung cancer via negative regulation of PI3K/Akt signaling pathway. Li B, Yuan Z, Jiang J, Rao Y. Biosci. Rep. 38 (2018)
  177. Antibody-assisted target identification reveals afatinib, an EGFR covalent inhibitor, down-regulating ribonucleotide reductase. Yu CH, Chou CC, Tu HF, Huang WC, Ho YY, Khoo KH, Lee MS, Chang GD. Oncotarget 9 21512-21529 (2018)
  178. Antiproliferative and Carbonic Anhydrase II Inhibitory Potential of Chemical Constituents from Lycium shawii and Aloe vera: Evidence from In Silico Target Fishing and In Vitro Testing. Ur Rehman N, Halim SA, Khan M, Hussain H, Hussain H, Yar Khan H, Khan A, Abbas G, Rafiq K, Al-Harrasi A. Pharmaceuticals (Basel) 13 (2020)
  179. Appropriate Sequence for Afatinib and Cisplatin Combination Improves Anticancer Activity in Head and Neck Squamous Cell Carcinoma. Longton E, Schmit K, Fransolet M, Clement F, Michiels C. Front Oncol 8 432 (2018)
  180. BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors. Miele E, Abballe L, Spinelli GP, Besharat ZM, Catanzaro G, Chiacchiarini M, Vacca A, Po A, Capalbo C, Ferretti E. BMC Cancer 20 129 (2020)
  181. Brain metastases in resected non-small cell lung cancer: The impact of different tyrosine kinase inhibitors. Yun PJ, Wang GC, Chen YY, Wu TH, Huang HK, Lee SC, Chang H, Huang TW. PLoS ONE 14 e0215923 (2019)
  182. Breaking bad family ties: Pan-ERBB blockers inhibit KRAS driven lung tumorigenesis. Moll HP, Casanova E. Mol Cell Oncol 5 e1513724 (2018)
  183. Case Reports Case Report: Afatinib-Induced Interstitial Pneumonia: Experiences and Lessons From Two Patients. Liu X, Ma B, Li T, Zhao L. Front Pharmacol 12 698447 (2021)
  184. Case series on the association between blood levels and side effects of afatinib maleate. Sato J, Morikawa N, Chiba R, Nihei S, Moriguchi S, Saito H, Yamauchi K, Kudo K. Cancer Chemother. Pharmacol. 80 545-553 (2017)
  185. Case Reports Clinical benefit from afatinib in an advanced squamous cell lung carcinoma patient harboring HER2 S310Y mutation: a case report. Gao Y, Zheng A, Zhu X, Song J, Xue Q. Onco Targets Ther 11 8705-8710 (2018)
  186. Clinical characterization of ERBB2 exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patients. Liu Z, Wu L, Cao J, Yang Z, Zhou C, Cao L, Wu H, Shen H, Jin M, Zhang Y, Mao X, Xiang J, Ma K, Li B, Zhang T, Hu Y. Onco Targets Ther 11 7323-7331 (2018)
  187. Comparison of T790M Acquisition Between Patients Treated with Afatinib and Gefitinib as First-Line Therapy: Retrospective Propensity Score Matching Analysis. Yoon BW, Kim JH, Lee SH, Choi CM, Rho JK, Yoon S, Lee DH, Kim SW, Jang TW, Lee JC. Transl Oncol 12 852-858 (2019)
  188. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types. Park S, Lee SY, Kim D, Sim YS, Ryu JS, Choi J, Lee SH, Ryu YJ, Lee JH, Chang JH. BMC Cancer 21 52 (2021)
  189. Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer. Zhang L, Li N, Liu M, Zheng B, Wu Z, Cai H. Cancer Manag Res 13 4263-4270 (2021)
  190. Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines. Plangger A, Rath B, Stickler S, Hochmair M, Lang C, Weigl L, Funovics M, Hamilton G. Discov Oncol 13 84 (2022)
  191. Defining and Targeting Esophagogastric Cancer Genomic Subsets With Patient-Derived Xenografts. Moy RH, Walch HS, Mattar M, Chatila WK, Molena D, Strong VE, Tang LH, Maron SB, Coit DG, Jones DR, Hechtman JF, Solit DB, Schultz N, de Stanchina E, Janjigian YY. JCO Precis Oncol 6 e2100242 (2022)
  192. Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor. He P, Niu S, Wang S, Shi X, Feng S, Du L, Zhang X, Ma Z, Yu B, Liu H. Acta Pharm Sin B 9 1193-1203 (2019)
  193. Discovery of a novel class anti-proliferative agents and potential inhibitors of EGFR tyrosine kinases based on 4-anilinotetrahydropyrido[4,3-d]pyrimidine scaffold: Design, synthesis and biological evaluations. Zhang Y, Zhang K, Zhao M, Zhang L, Qin M, Guo S, Zhao Y, Gong P. Bioorg. Med. Chem. 23 4591-4607 (2015)
  194. Discovery of novel quinazoline derivatives bearing semicarbazone moiety as potent EGFR kinase inhibitors. Tu Y, Wang C, Yang Z, Zhao B, Lai L, Yang Q, Zheng P, Zhu W. Comput Struct Biotechnol J 16 462-478 (2018)
  195. Drug Repositioning and Subgroup Discovery for Precision Medicine Implementation in Triple Negative Breast Cancer. Al-Taie Z, Hannink M, Mitchem J, Papageorgiou C, Shyu CR. Cancers (Basel) 13 6278 (2021)
  196. ERBB and P-glycoprotein inhibitors break resistance in relapsed neuroblastoma models through P-glycoprotein. Rösch L, Herter S, Najafi S, Ridinger J, Peterziel H, Cinatl J, Jones DTW, Michaelis M, Witt O, Oehme I. Mol Oncol 17 37-58 (2023)
  197. Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam. Vu TH, Nguyen HTT, Dao LK, Duong CK, Nguyen CV, Doan TT, Nguyen HTT, Hoang HH, Dinh DK, Le GV, Vu TT, Truong MC, Nguyen LT. Asian Pac J Cancer Prev 22 1581-1590 (2021)
  198. Effects of polymorphisms in pregnane X receptor and ABC transporters on afatinib in Japanese patients with non-small cell lung cancer: pharmacogenomic-pharmacokinetic and exposure-response analysis. Yokota H, Sato K, Sakamoto S, Okuda Y, Asano M, Takeda M, Nakayama K, Miura M. Cancer Chemother Pharmacol 92 315-324 (2023)
  199. Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations. Wang S, Xing P, Yang K, Hao X, Ma D, Mu Y, Li J. Thorac Cancer 10 1461-1468 (2019)
  200. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. Qi YT, Hou Y, Qi LC. Technol Cancer Res Treat 19 1533033820940426 (2020)
  201. Elucidation of chemical modifier reactivity towards peptides and proteins and the analysis of specific fragmentation by matrix-assisted laser desorption/ionization collision-induced dissociation tandem mass spectrometry. Rühl M, Kühn B, Roos J, Maier TJ, Steinhilber D, Karas M. Rapid Commun. Mass Spectrom. 33 Suppl 1 40-49 (2019)
  202. Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations. Chang GC, Lam DC, Tsai CM, Chen YM, Shih JY, Aggarwal S, Wang S, Kim SW, Kim YC, Wahid I, Li R, Lim DW, Sriuranpong V, Chan RT, Lorence RM, Carriere P, Raabe C, Cseh A, Park K. Int J Clin Oncol 26 841-850 (2021)
  203. First-line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation-positive non-small cell lung cancer. Su PL, Chen CW, Wu YL, Lin CC, Su WC. Thorac Cancer 12 287-296 (2021)
  204. Case Reports Genomic Analysis of Tumors from Patients with Glioblastoma with Long-Term Response to Afatinib. Owen S, Alken S, Alshami J, Guiot MC, Kavan P, Reardon DA, Muanza T, Gibson N, Pemberton K, Solca F, Cseh A, Saran F. Onco Targets Ther 15 367-380 (2022)
  205. Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies. Cappuzzo F, Soo R, Hochmair M, Schuler M, Lam KC, Stehle G, Cseh A, Lorence RM, Linden S, Forman ND, Hilbe W, Jazieh AR, Tsai CM. Future Oncol 14 1477-1486 (2018)
  206. High-Trough Plasma Concentration of Afatinib Is Associated with Dose Reduction. Takahashi T, Terazono H, Suetsugu T, Sugawara H, Arima J, Nitta M, Tanabe T, Okutsu K, Ikeda R, Mizuno K, Inoue H, Takeda Y. Cancers (Basel) 13 3425 (2021)
  207. Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer. Bonello M, Sims AH, Langdon SP. Cancer Biol Med 15 375-388 (2018)
  208. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation. Miyashita Y, Ko R, Shimada N, Mitsuishi Y, Miura K, Matsumoto N, Asao T, Shukuya T, Shibayama R, Koyama R, Takahashi K. Thorac Cancer 12 329-338 (2021)
  209. In-silico activity prediction and docking studies of some 2, 9-disubstituted 8-phenylthio/phenylsulfinyl-9h-purine derivatives as Anti-proliferative agents. Ibrahim MT, Uzairu A, Shallangwa GA, Uba S. Heliyon 6 e03158 (2020)
  210. Inhibitory Effects of HangAmDan-B1 (HAD-B1) Combined With Afatinib on H1975 Lung Cancer Cell-Bearing Mice. Kang HJ, Kim J, Cho SH, Park SJ, Yoo HS, Kang IC. Integr Cancer Ther 18 1534735419830765 (2019)
  211. Letter LUX-Lung 7: is there enough data for a final conclusion? Orlandi A, Calegari MA, Barone C. Lancet Oncol. 17 e267-e268 (2016)
  212. Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population. Yang F, Huang X, Sun C, Li J, Wang B, Yan M, Jin F, Wang H, Zhang J, Fu P, Zeng T, Wang J, Li W, Li Y, Yang M, Li J, Wu H, Fu Z, Yin Y, Jiang Z. BMC Cancer 20 255 (2020)
  213. Localization and Accumulation Studies of Dacomitinib in Rat Intestines and Skin by Immunohistochemistry. Yamamoto Y, Saita T, Oka A, Kataoka H, Shin M. Acta Histochem Cytochem 52 101-106 (2019)
  214. Letter Long-Term Survival of Over 6 Years with Afatinib Sequential Treatment in a Patient with EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Case Report. Tu HY, Li YS, Yang JJ, Chen HJ, Jiang BY, Zhong WZ, Yang XN, Wu YL. Clin Drug Investig 41 483-488 (2021)
  215. Long-lasting response to afatinib that persisted after treatment discontinuation in a case of EGFR-mutated lung adenocarcinoma. Yamanaka Y, Seki Y, Ishikawa T, Kuwano K. BMJ Case Rep 12 (2019)
  216. Long-term Survival With Afatinib in a Patient With Lung Adenocarcinoma Harboring Double Uncommon EGFR L861Q and G719X Mutations. Ohara G, Okauchi S, Sasatani Y, Shiozawa T, Yamada H, Miyazaki K, Satoh H. In Vivo 34 1459-1462 (2020)
  217. Long-term efficacy of afatinib in a patient with squamous cell carcinoma of the lung and multiple ERBB family aberrations: afatinib in ERBB+ lung squamous cell carcinoma. Jian H, Han Y, Yu Y, Lu S. Anticancer Drugs 30 873-878 (2019)
  218. Long-term response to second-line afatinib treatment for advanced squamous cell carcinoma non-small cell lung cancer: a rare case report. Sun M, Guo Y, Wang X, Sun C, Shao J, Xu Y, Qiu S, Ma K. J Int Med Res 48 300060520964700 (2020)
  219. Mechanisms of acquired resistance to afatinib clarified with liquid biopsy. Nakamura T, Nakashima C, Komiya K, Kitera K, Hirai M, Kimura S, Aragane N. PLoS ONE 13 e0209384 (2018)
  220. Medication adjustment of afatinib and combination therapy with sitagliptin for alleviating afatinib-induced diarrhea in rats. Zhang L, Hu A, Wang Y, Yang Y, Liu Y, Xu L, Wang L, Cheng Z. Neoplasia 43 100922 (2023)
  221. Minimalist linkers suitable for irreversible inhibitors in simultaneous proteome profiling, live-cell imaging and drug screening. Guo C, Chang Y, Wang X, Zhang C, Hao P, Ding K, Li Z. Chem. Commun. (Camb.) 55 834-837 (2019)
  222. Molecularly Targeted Photothermal Ablation of Epidermal Growth Factor Receptor-Expressing Cancer Cells with a Polypyrrole-Iron Oxide-Afatinib Nanocomposite. Rethi L, Mutalik C, Rethi L, Chiang WH, Lee HL, Pan WY, Yang TS, Chiou JF, Chen YJ, Chuang EY, Lu LS. Cancers (Basel) 14 5043 (2022)
  223. Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Exploratory Study to Evaluate the Efficacy and Safety of HAD-B1 for Dose-Finding in EGFR Mutation Positive and Locally Advanced or Metastatic NSCLC Subjects Who Need Afatinib Therapy. Ko EJ, Kwag EB, Park JH, Park SJ, Son JW, Yoon SH, Shin SH, Yoo HS. Integr Cancer Ther 20 15347354211037917 (2021)
  224. Multi-disciplinary proactive follow-up algorithm for patients with advanced NSCLC receiving afatinib. Cheema PK, Thawer A, Leake J, Cheng SY, Khanna S, Charles Victor J. Support Care Cancer 27 1029-1039 (2019)
  225. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2+ve breast cancer metastasis. Nagpal A, Redvers RP, Ling X, Ayton S, Fuentes M, Tavancheh E, Diala I, Lalani A, Loi S, David S, Anderson RL, Smith Y, Merino D, Denoyer D, Pouliot N. Breast Cancer Res. 21 94 (2019)
  226. Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells. Chen L, Zhang Y, Liu J, Wang W, Li X, Zhao L, Wang W, Li B. Eur J Med Chem 138 689-697 (2017)
  227. Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib. De Pauw I, Lardon F, Van den Bossche J, Baysal H, Pauwels P, Peeters M, Vermorken JB, Wouters A. Cancers (Basel) 11 (2019)
  228. PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations. Dong Q, Yu P, Ye L, Zhang J, Wang H, Zou F, Tian J, Kurihara H. Sci Rep 9 5692 (2019)
  229. Pharmacist-led patient education and adverse event management in patients with non-small cell lung cancer receiving afatinib in a community-based, real-world clinical setting. Khrystolubova N, Shieh M, Patel AJ, Bailey R. J Oncol Pharm Pract 26 13-22 (2020)
  230. Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors. Hiret S, Isambert N, Gomez-Roca C, Bennouna J, Sassi M, de Mont-Serrat H, Fan J, Schnell D, Delord JP. Invest New Drugs 36 1044-1059 (2018)
  231. Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2. Bahleda R, Varga A, Bergé Y, Soria JC, Schnell D, Tschoepe I, Uttenreuther-Fischer M, Delord JP. Br. J. Cancer 118 344-352 (2018)
  232. Phase II Study of Low-Dose Afatinib Maintenance Treatment Among Patients with EGFR-Mutated Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 (NJLCG1601). Nakamura A, Tanaka H, Saito R, Suzuki A, Harada T, Inoue S, Yamada T, Nakagawa T, Jingu D, Sugawara S. Oncologist 25 e1451-e1456 (2020)
  233. Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer. Nakao K, Kobuchi S, Marutani S, Iwazaki A, Tamiya A, Isa S, Okishio K, Kanazu M, Tamiya M, Hirashima T, Imai K, Sakaeda T, Atagi S. Sci Rep 9 18202 (2019)
  234. Predictors of Acquired T790M Mutation in Patients Failing First- or Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors. Chai CS, Liam CK, Poh ME, Ong DB, Pang YK, Cheah PL, Ho GF, Alip A. Cancer Manag Res 12 5439-5450 (2020)
  235. Prophylactic Dermatologic Treatment of Afatinib-Induced Skin Toxicities in Patients with Metastatic Lung Cancer: A Pilot Study. Fuggetta MP, Migliorino MR, Ricciardi S, Osman G, Iacono D, Leone A, Lombardi A, Ravagnan G, Greco S, Remotti D, Romano MCP. Scientifica (Cairo) 2019 9136249 (2019)
  236. Quantification of [18F]afatinib using PET/CT in NSCLC patients: a feasibility study. van de Stadt EA, Yaqub M, Lammertsma AA, Poot AJ, Schober PR, Schuit RC, Smit EF, Bahce I, Hendrikse NH. EJNMMI Res 10 97 (2020)
  237. Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity. Marret G, Temam S, Kamal M, Even C, Delord JP, Hoffmann C, Dolivet G, Malard O, Fayette J, Capitain O, Vergez S, Geoffrois L, Rolland F, Zrounba P, Laccourreye L, Saada-Bouzid E, Aide N, Bénavent V, Klijianenko J, Lamy C, Girard E, Vacher S, Masliah-Planchon J, de Koning L, Puard V, Borcoman E, Jimenez M, Bièche I, Gal J, Le Tourneau C. Sci Rep 13 22524 (2023)
  238. Real-World Treatment Outcomes and Safety of Afatinib in Advanced Squamous Cell Lung Cancer Progressed after Platinum-Based Doublet Chemotherapy and Immunotherapy (SPACE Study). Ji W, Oh IJ, Park CK, Lee SY, Choi J, Lee JC, Kim J, Lee SH. Cancers (Basel) 15 5568 (2023)
  239. Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea. Lee SY, Choi CM, Chang YS, Lee KY, Kim SJ, Yang SH, Ryu JS, Lee JE, Lee SY, Park JY, Kim YC, Oh IJ, Jung CY, Lee SH, Yoon SH, Choi J, Jang TW. Transl Lung Cancer Res 10 4353-4367 (2021)
  240. Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study. Ho GF, Chai CS, Alip A, Wahid MIA, Abdullah MM, Foo YC, How SH, Zaatar A, Lam KS, Leong KW, Low JS, Yusof MM, Lee EC, Toh YY, Liam CK. BMC Cancer 19 896 (2019)
  241. Real-world outcomes of first- and second-generation tyrosine kinase inhibitors first-line in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: A retrospective observational cohort study. Ng WW, Lin CC, Cheng CY, Jiang JS, Kao SJ, Yeh DY. PLoS One 16 e0253335 (2021)
  242. Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib. Tamura K, Nukiwa T, Gemma A, Yamamoto N, Mizushima M, Ochai K, Ikeda R, Azuma H, Nakanishi Y. Int. J. Clin. Oncol. 24 917-926 (2019)
  243. Relationship between Plasma Concentrations of Afatinib and the Onset of Diarrhea in Patients with Non-Small Cell Lung Cancer. Yokota H, Sato K, Sakamoto S, Okuda Y, Asano M, Takeda M, Nakayama K, Miura M. Biology (Basel) 10 1054 (2021)
  244. Case Reports Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification. Meedendorp AD, Ter Elst A, 't Hart NA, Groen HJM, Schuuring E, van der Wekken AJ. Front Oncol 8 176 (2018)
  245. Site-Specific Activity-Based Protein Profiling Using Phosphonate Handles. van Bergen W, Hevler JF, Wu W, Baggelaar MP, Heck AJR. Mol Cell Proteomics 22 100455 (2023)
  246. Structural elements that enable specificity for mutant EGFR kinase domains with next-generation small-molecule inhibitors. Damghani T, Wittlinger F, Beyett TS, Eck MJ, Laufer SA, Heppner DE. Methods Enzymol 685 171-198 (2023)
  247. Case Reports Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report. Saito Z, Imakita T, Ito T, Oi I, Kanai O, Fujita K, Tachibana H, Mio T. Case Rep Oncol 16 1100-1106 (2023)
  248. Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumab. Tamiya M, Kunimasa K, Nishino K, Matsumoto S, Kawachi H, Kuno K, Inoue T, Kuhara H, Imamura F, Goto K, Kumagai T. Invest New Drugs 39 232-236 (2021)
  249. Case Reports Successful treatment with gefitinib after Stevens-Johnson syndrome associated with afatinib therapy in a patient with adenocarcinoma of the lung. Otsuka T, Tanaka A, Azukizawa H, Sasaki S, Ishijima M, Matsuki T, Osa A, Nakatani T, Kuroyama M, Hirata H, Kijima T. Int Cancer Conf J 6 38-41 (2017)
  250. Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer. Plangger A, Rath B, Hochmair M, Funovics M, Neumayer C, Zeillinger R, Hamilton G. Invest New Drugs 40 215-223 (2022)
  251. Synthesis of aspirin-curcumin mimic conjugates of potential antitumor and anti-SARS-CoV-2 properties. Srour AM, Panda SS, Mostafa A, Fayad W, El-Manawaty MA, A F Soliman A, Moatasim Y, El Taweel A, Abdelhameed MF, Bekheit MS, Ali MA, Girgis AS. Bioorg Chem 117 105466 (2021)
  252. The Alkyne Moiety as a Latent Electrophile in Irreversible Covalent Small Molecule Inhibitors of Cathepsin K. Mons E, Jansen IDC, Loboda J, van Doodewaerd BR, Hermans J, Verdoes M, van Boeckel CAA, van Veelen PA, Turk B, Turk D, Ovaa H. J. Am. Chem. Soc. 141 3507-3514 (2019)
  253. The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan. Huang YH, Hsu KH, Tseng JS, Yang TY, Chen KC, Su KY, Yu SL, Chen JJW, Chang GC. Target Oncol 17 295-306 (2022)
  254. The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations. Kagawa Y, Hayashida T, Liu J, Mori S, Izumi H, Kumagai S, Udagawa H, Hattori N, Goto K, Kobayashi SS. JTO Clin Res Rep 4 100462 (2023)
  255. The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma. Truini A, Starrett JH, Stewart T, Ashtekar K, Walther Z, Wurtz A, Lu D, Park JH, DeVeaux M, Song X, Gettinger S, Zelterman D, Lemmon MA, Goldberg SB, Politi K. Clin. Cancer Res. 25 6382-6391 (2019)
  256. The Impact of Afatinib on Survival in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. Wang C, Li Y, Ke L, Cao L, Fan P, Wu Z, Wu Q. J Cancer 10 885-892 (2019)
  257. The aftermath of LUX-Lung 7 study-what have we learnt from it? Lee VH. Ann Transl Med 4 294 (2016)
  258. The clinical features of squamous cell lung carcinoma with sensitive EGFR mutations. Taniguchi Y, Matsumoto Y, Furukawa R, Ohara S, Usui K. Int. J. Clin. Oncol. 23 452-457 (2018)
  259. The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC. Tamiya M, Tamiya A, Okamoto N, Taniguchi Y, Nishino K, Atagi S, Hirashima T, Imamura F, Kumagai T, Suzuki H. Sci Rep 11 9629 (2021)
  260. Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Xie J, Zou Y, Gao T, Xie L, Tan D, Xie X. Cancer Control 29 10732748221099230 (2022)
  261. Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22. Jung HA, Hong MH, Lee HW, Lee KH, Kim IH, Min YJ, Ahn HK, Shim BY, Choi YH, Lee YG, Kim JA, Jang JS, Shin SH, Park KU, Kang JH, Park K. Transl Lung Cancer Res 11 1369-1379 (2022)
  262. Editorial Update on afatinib-based combination regimens for the treatment of EGFR mutation-positive non-small-cell lung cancer. Bennouna J. Future Oncol 13 1829-1833 (2017)
  263. Xanthatin inhibits STAT3 and NF-κB signalling by covalently binding to JAK and IKK kinases. Liu M, Xiao CQ, Sun MW, Tan MJ, Hu LH, Yu Q. J. Cell. Mol. Med. 23 4301-4312 (2019)


Quick links